Breaking News

Wednesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Initiation
Fly Intel: Top five analyst initiations » 10:08
06/03/20
06/03
10:08
06/03/20
10:08
ADPT

Adaptive Biotechnologies

$40.80 /

+2.15 (+5.56%)

, DECK

Deckers Brands

$208.43 /

+4.43 (+2.17%)

, ALLE

Allegion

$102.69 /

+2.685 (+2.68%)

, WMG

Warner Music

$0.00 /

+ (+0.00%)

, EXP

Eagle Materials

$71.82 /

+2.22 (+3.19%)

Catch up on today's…

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Adaptive Biotechnologies (ADPT) initiated with a Buy at Goldman Sachs. 2. Deckers Brands (DECK) initiated with an Outperform at Cowen. 3. Allegion (ALLE) initiated with a Market Perform at William Blair. 4. Warner Music (WMG) initiated with a Neutral at Atlantic Equities. 5. Eagle Materials (EXP) reinstated with a Neutral at Goldman Sachs. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
WMG Warner Music
$0.00 /

+ (+0.00%)

EXP Eagle Materials
$71.82 /

+2.22 (+3.19%)

DECK Deckers Brands
$208.43 /

+4.43 (+2.17%)

ALLE Allegion
$102.69 /

+2.685 (+2.68%)

ADPT Adaptive Biotechnologies
$40.80 /

+2.15 (+5.56%)

ADPT Adaptive Biotechnologies
$40.80 /

+2.15 (+5.56%)

06/03/20 Goldman Sachs
Adaptive Biotechnologies initiated with a Buy at Goldman Sachs
05/19/20 Guggenheim
Adaptive Biotechnologies price target raised to $50 from $44 at Guggenheim
05/13/20 JPMorgan
Adaptive reported 'healthy' Q1 results, says JPMorgan
03/11/20 JPMorgan
JPMorgan continues to recommend select exposure to Life Science Tools
DECK Deckers Brands
$208.43 /

+4.43 (+2.17%)

06/03/20 Cowen
Cowen likes its brand durability, initiated Deckers Brands with Outperform
06/03/20 Cowen
Deckers Brands initiated with an Outperform at Cowen
05/22/20 BTIG
Deckers Brands price target raised to $208 from $201 at BTIG
05/22/20 Susquehanna
Deckers Brands price target raised to $200 from $175 at Susquehanna
ALLE Allegion
$102.69 /

+2.685 (+2.68%)

06/03/20 William Blair
William Blair starts Allegion at Market Perform due to valuation
06/03/20 William Blair
Allegion initiated with a Market Perform at William Blair
05/21/20 Barclays
Allegion downgraded to Underweight from Equal Weight at Barclays
04/27/20 Imperial Capital
Allegion price target lowered to $100 from $120 at Imperial Capital
WMG Warner Music
$0.00 /

+ (+0.00%)

06/03/20 Atlantic Equities
Warner Music initiated with a Neutral at Atlantic Equities
EXP Eagle Materials
$71.82 /

+2.22 (+3.19%)

06/03/20 Goldman Sachs
Eagle Materials reinstated with a Neutral at Goldman Sachs
05/22/20 JPMorgan
JPMorgan upgrades Martin Marietta with 17% upside into year-end
05/20/20 Raymond James
Eagle Materials upgraded to Outperform from Market Perform at Raymond James
05/20/20 Raymond James
Eagle Materials upgraded to Outperform from Market Perform at Raymond James
EXP Eagle Materials
$71.82 /

+2.22 (+3.19%)

DECK Deckers Brands
$208.43 /

+4.43 (+2.17%)

ALLE Allegion
$102.69 /

+2.685 (+2.68%)

ADPT Adaptive Biotechnologies
$40.80 /

+2.15 (+5.56%)

  • 03
    Jun
WMG Warner Music
$0.00 /

+ (+0.00%)

EXP Eagle Materials
$71.82 /

+2.22 (+3.19%)

WMG Warner Music
$0.00 /

+ (+0.00%)

EXP Eagle Materials
$71.82 /

+2.22 (+3.19%)

DECK Deckers Brands
$208.43 /

+4.43 (+2.17%)

ADPT Adaptive Biotechnologies
$40.80 /

+2.15 (+5.56%)

Initiation
Adaptive Biotechnologies initiated with a Buy at Goldman Sachs » 05:03
06/03/20
06/03
05:03
06/03/20
05:03
ADPT

Adaptive Biotechnologies

$38.65 /

-0.43 (-1.10%)

, MSFT

Microsoft

$184.95 /

+2.09 (+1.14%)

Goldman Sachs analyst…

Goldman Sachs analyst Salveen Richter initiated coverage of Adaptive Biotechnologies (ADPT) with a Buy rating and $60 price target. The launch of the Microsoft-partnered immunoSEQ Dx in 2021, a clinical diagnostic incorporating machine learning to match immune responses to disease states, and Adaptive's drug discovery pipeline, including a cell therapy collaboration in oncology with Genentech and future sole expansion into autoimmune disease alongside cancer vaccines, provide "two key growth levers," Richter tells investors in a research note. The analyst is positive on the company's "innovative technology platform and future trajectory of the business model."

ShowHide Related Items >><<
MSFT Microsoft
$184.95 /

+2.09 (+1.14%)

ADPT Adaptive Biotechnologies
$38.65 /

-0.43 (-1.10%)

ADPT Adaptive Biotechnologies
$38.65 /

-0.43 (-1.10%)

05/19/20 Guggenheim
Adaptive Biotechnologies price target raised to $50 from $44 at Guggenheim
05/13/20 JPMorgan
Adaptive reported 'healthy' Q1 results, says JPMorgan
03/11/20 JPMorgan
JPMorgan continues to recommend select exposure to Life Science Tools
01/09/20 JPMorgan
Danaher, Thermo named JPMorgan's top 2020 picks in Life Science Tools
MSFT Microsoft
$184.95 /

+2.09 (+1.14%)

06/02/20 Wells Fargo
Microsoft price target raised to $250 from $205 at Wells Fargo
06/02/20 Cowen
Cowen starts Slack with Outperform given 'major booster shot' from COVID
05/28/20 Needham
Workday price target raised to $200 from $175 at Needham
05/27/20 Summit Insights
Microsoft initiated with a Buy at Summit Insights
MSFT Microsoft
$184.95 /

+2.09 (+1.14%)

ADPT Adaptive Biotechnologies
$38.65 /

-0.43 (-1.10%)

MSFT Microsoft
$184.95 /

+2.09 (+1.14%)

MSFT Microsoft
$184.95 /

+2.09 (+1.14%)

ADPT Adaptive Biotechnologies
$38.65 /

-0.43 (-1.10%)

MSFT Microsoft
$184.95 /

+2.09 (+1.14%)

MSFT Microsoft
$184.95 /

+2.09 (+1.14%)

Monday
Recommendations
Alexion price target raised to $138 from $120 at Wedbush » 08:23
06/01/20
06/01
08:23
06/01/20
08:23
ALXN

Alexion

$120.03 /

+5.595 (+4.89%)

, AMGN

Amgen

$230.13 /

+6.11 (+2.73%)

Wedbush analyst Laura…

Wedbush analyst Laura Chico raised the firm's price target on Alexion (ALXN) to $138 from $120 and keeps an Outperform rating on the shares. The analyst notes that the company issued an 8-k disclosing that it has reached a settlement agreement with Amgen (AMGN) in the IPR proceeding. Chico sees the settlement agreement affording clarity and additional timing for Alexion to execute on its Ultomiris diversification strategy.

ShowHide Related Items >><<
AMGN Amgen
$230.13 /

+6.11 (+2.73%)

ALXN Alexion
$120.03 /

+5.595 (+4.89%)

ALXN Alexion
$120.03 /

+5.595 (+4.89%)

06/01/20 Credit Suisse
Alexion price target raised to $147 from $142 at Credit Suisse
05/28/20 Raymond James
Raymond James keeps Outperform on Alexion after IP settlement analysis
05/28/20 Piper Sandler
Alexion settlement could 'clear the deck' for acquirer, says Piper Sandler
05/28/20 Cowen
Alexion settlement may yield upside surprise, says Cowen
AMGN Amgen
$230.13 /

+6.11 (+2.73%)

05/28/20 Stifel
Alexion, Amgen appear to have agreed to settlement deal, says Stifel
AMGN Amgen
$230.13 /

+6.11 (+2.73%)

ALXN Alexion
$120.03 /

+5.595 (+4.89%)

AMGN Amgen
$230.13 /

+6.11 (+2.73%)

ALXN Alexion
$120.03 /

+5.595 (+4.89%)

AMGN Amgen
$230.13 /

+6.11 (+2.73%)

ALXN Alexion
$120.03 /

+5.595 (+4.89%)

ALXN Alexion
$120.03 /

+5.595 (+4.89%)

Recommendations
Alexion price target raised to $147 from $142 at Credit Suisse » 07:22
06/01/20
06/01
07:22
06/01/20
07:22
ALXN

Alexion

$120.03 /

+5.595 (+4.89%)

, AMGN

Amgen

$230.13 /

+6.11 (+2.73%)

Credit Suisse analyst…

Credit Suisse analyst Martin Auster raised the firm's price target on Alexion (ALXN) to $147 from $142 and keeps an Outperform rating on the shares. The analyst notes that Alexion has announced initial details of a settlement agreement with Amgen (AMGN) to terminate three pending IPRs. Under the terms of the settlement agreement, Alexion will grant Amgen a non-exclusive, royalty-free license for eculizumab effective March 1, 2025, he adds. Auster sees the settlement agreement as removal of a meaningful overhang that may prompt investor reengagement with shares.

ShowHide Related Items >><<
AMGN Amgen
$230.13 /

+6.11 (+2.73%)

ALXN Alexion
$120.03 /

+5.595 (+4.89%)

ALXN Alexion
$120.03 /

+5.595 (+4.89%)

05/28/20 Raymond James
Raymond James keeps Outperform on Alexion after IP settlement analysis
05/28/20 Piper Sandler
Alexion settlement could 'clear the deck' for acquirer, says Piper Sandler
05/28/20 Cowen
Alexion settlement may yield upside surprise, says Cowen
05/28/20 Stifel
Alexion, Amgen appear to have agreed to settlement deal, says Stifel
AMGN Amgen
$230.13 /

+6.11 (+2.73%)

05/22/20 Piper Sandler
Harpoon Therapeutics initiated with an Overweight at Piper Sandler
AMGN Amgen
$230.13 /

+6.11 (+2.73%)

ALXN Alexion
$120.03 /

+5.595 (+4.89%)

AMGN Amgen
$230.13 /

+6.11 (+2.73%)

ALXN Alexion
$120.03 /

+5.595 (+4.89%)

AMGN Amgen
$230.13 /

+6.11 (+2.73%)

ALXN Alexion
$120.03 /

+5.595 (+4.89%)

ALXN Alexion
$120.03 /

+5.595 (+4.89%)

Over a week ago
Hot Stocks
Fly Intel: Top five weekend stock stories » 20:22
05/31/20
05/31
20:22
05/31/20
20:22
AMZN

Amazon.com

$2,442.37 /

+42.04 (+1.75%)

, AAPL

Apple

$317.94 /

-0.38 (-0.12%)

, TGT

Target

$122.50 /

+4.055 (+3.42%)

, ALXN

Alexion

$120.03 /

+5.595 (+4.89%)

, AMGN

Amgen

$230.13 /

+6.11 (+2.73%)

, TWTR

Twitter

$30.97 /

-0.63 (-1.99%)

, MSFT

Microsoft

$183.30 /

+2.06 (+1.14%)

, GOOG

Alphabet

$1,430.80 /

+14.43 (+1.02%)

, GOOGL

Alphabet Class A

$1,435.82 /

+17.61 (+1.24%)

, FB

Facebook

$223.10 /

-2.04 (-0.91%)

, COTY

Coty

$3.63 /

-0.56 (-13.38%)

, SAVE

Spirit Airlines

$12.96 /

+0.035 (+0.27%)

, LUV

Southwest

$32.11 /

-0.44 (-1.35%)

, DAL

Delta Air Lines

$25.19 /

-0.47 (-1.83%)

, STAY

Extended Stay America

$11.50 /

+0.17 (+1.50%)

, LIND

Lindblad Expeditions

$7.87 /

+0.2 (+2.61%)

, MPC

Marathon Petroleum

$35.13 /

-0.08 (-0.23%)

, LVS

Las Vegas Sands

$47.96 /

-0.62 (-1.28%)

, CTRE

CareTrust REIT

$18.62 /

-0.73 (-3.77%)

, VLO

Valero

$66.62 /

-0.59 (-0.88%)

, PSX

Phillips 66

$78.30 /

-0.35 (-0.45%)

, CQP

Cheniere Energy Partners

$33.91 /

+0.87 (+2.63%)

, BAESY

BAE Systems

$0.00 /

+ (+0.00%)

Catch up on the…

Catch up on the weekend's top five stories with this list compiled by The Fly: 1. Amazon (AMZN) scaled back deliveries and adjusted routes in cities including Chicago and Los Angeles, Apple (APPL) kept some outlets shut, while Target (TGT) extended store closures nationwide after the death of George Floyd sparked demonstrations across the country, Bloomberg's Spencer Soper and James Ludden reported. "We are monitoring the situation closely and in a handful of cities we adjusted routes or scaled back typical operations to ensure the safety of our teams," an Amazon spokeswoman told Bloomberg News. 2. According to a company's filing, "On May 28, 2020, Alexion Pharmaceuticals [ALXN] and Amgen [AMGN] entered into a Confidential Settlement and License Agreement to settle three inter partes review proceedings at the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office initiated by Amgen that the Company previously disclosed. Pursuant to the Settlement Agreement, the company and Amgen have agreed to file a motion with the PTAB to terminate each of the pending IPRs. In addition, effective March 1, 2025 (or an earlier date in certain circumstances), the company grants to Amgen (and its affiliates and certain partners) a non-exclusive, royalty-free, license under U.S. patents and patent applications related to eculizumab and various aspects of the eculizumab product that the company currently markets and sells under the tradename SOLIRIS. This license will allow Amgen (and its affiliates and certain partners), effective March 1, 2025, the right to make, have made, use, import, have imported, sell, have sold, offer for sale, have offered for sale, distribute, and have distributed in or for the U.S., an eculizumab product." 3. President Trump declared war on Twitter (TWTR), and Wall Street trembled, with the stock shedding 9% of its value from Wednesday to Friday as investors digested the financial implications of the company having the world's most powerful person-and its most loyal user-as a mortal enemy, Eric Savitz wrote in this week's edition of Barron's. While tech stocks have outperformed during the pandemic, the Twitter-White House spat brings back a bad memory from 2019 and could mean a return of the "tech lash," another challenge for stocks this summer, the author added. Twitter's 9% decline equated to $2.4B in lost market value, the publication notes, pointing out that a similar move applied to the tech giants, would be far more substantial. Microsoft (MSFT), Apple, Amazon, Alphabet (GOOGL), and Facebook (FB) have a combined market value of $5.6T. A 9% haircut comes to $500B, Savitz contended. 4. Coty (COTY) is set to appoint its fourth new chief executive in less than four years, as the cosmetics and fragrance maker strives to revive slumping sales and reduce its burdensome debt load, The Wall Street Journal's Ben Dummett and Sharon Terlep reported. Peter Harf, Coty's current chairman, will also assume the CEO role as soon as Monday, the authors noted, citing people familiar with the matter. 5. Spirit Airlines (SAVE), Southwest Airlines (LUV), Delta Air Lines (DAL), Extended Stay America (STAY), Lindblad Expeditions (LIND), Marathon Petroleum (MPC), Las Vegas Sands (LVS), CareTrust (CTRE), Valero Energy (VLO) and Phillips 66 (PSX), Cheniere Energy Partners (CQP), BAE Systems (BAESY) saw positive mentions in this week's edition of Barron's.

ShowHide Related Items >><<
VLO Valero
$66.62 /

-0.59 (-0.88%)

TWTR Twitter
$30.97 /

-0.63 (-1.99%)

TGT Target
$122.50 /

+4.055 (+3.42%)

STAY Extended Stay America
$11.50 /

+0.17 (+1.50%)

SAVE Spirit Airlines
$12.96 /

+0.035 (+0.27%)

PSX Phillips 66
$78.30 /

-0.35 (-0.45%)

MSFT Microsoft
$183.30 /

+2.06 (+1.14%)

MPC Marathon Petroleum
$35.13 /

-0.08 (-0.23%)

LVS Las Vegas Sands
$47.96 /

-0.62 (-1.28%)

LUV Southwest
$32.11 /

-0.44 (-1.35%)

LIND Lindblad Expeditions
$7.87 /

+0.2 (+2.61%)

GOOG Alphabet
$1,430.80 /

+14.43 (+1.02%)

FB Facebook
$223.10 /

-2.04 (-0.91%)

DAL Delta Air Lines
$25.19 /

-0.47 (-1.83%)

CTRE CareTrust REIT
$18.62 /

-0.73 (-3.77%)

CQP Cheniere Energy Partners
$33.91 /

+0.87 (+2.63%)

COTY Coty
$3.63 /

-0.56 (-13.38%)

BAESY BAE Systems
$0.00 /

+ (+0.00%)

AMZN Amazon.com
$2,442.37 /

+42.04 (+1.75%)

AMGN Amgen
$230.13 /

+6.11 (+2.73%)

ALXN Alexion
$120.03 /

+5.595 (+4.89%)

AAPL Apple
$317.94 /

-0.38 (-0.12%)

AMZN Amazon.com
$2,442.37 /

+42.04 (+1.75%)

05/27/20 Morgan Stanley
Amazon deal could open door for ridesharing competition, says Morgan Stanley
05/18/20 Bernstein
Amazon not building standalone overnight network, says Bernstein
05/14/20 KeyBanc
Farfetch, Nordstrom, Revolve could be impacted by Amazon offering, says KeyBanc
05/12/20 Barrington
Amazon interest in AMC 'not outside the realm of possibility,' says Barrington
AAPL Apple
$317.94 /

-0.38 (-0.12%)

05/28/20 JPMorgan
Apple price target raised to $365 from $350 at JPMorgan
05/27/20 BofA
Apple price target raised to $340 from $320 at BofA
05/27/20 Jefferies
Apple price target raised to $370 from $350 at Jefferies
05/27/20 Deutsche Bank
Apple price target raised to $320 from $305 at Deutsche Bank
TGT Target
$122.50 /

+4.055 (+3.42%)

05/21/20 Deutsche Bank
Target price target raised to $131 from $121 at Deutsche Bank
05/21/20 Nomura Instinet
Target price target raised to $135 from $121 at Nomura Instinet
05/21/20 BMO Capital
Target price target raised to $135 from $125 at BMO Capital
05/21/20 Barclays
Target price target raised to $135 from $120 at Barclays
ALXN Alexion
$120.03 /

+5.595 (+4.89%)

05/28/20 Raymond James
Raymond James keeps Outperform on Alexion after IP settlement analysis
05/28/20 Piper Sandler
Alexion settlement could 'clear the deck' for acquirer, says Piper Sandler
05/28/20 Cowen
Alexion settlement may yield upside surprise, says Cowen
05/28/20 Stifel
Alexion, Amgen appear to have agreed to settlement deal, says Stifel
AMGN Amgen
$230.13 /

+6.11 (+2.73%)

05/22/20 Piper Sandler
Harpoon Therapeutics initiated with an Overweight at Piper Sandler
TWTR Twitter
$30.97 /

-0.63 (-1.99%)

05/29/20 Baird
Twitter, Facebook pullbacks would likely be buying opportunities, says Baird
05/29/20 JPMorgan
Trump order may put 'overhang' on big tech in coming months, says JPMorgan
05/27/20 Cowen
Cowen says Twitter 'will be fine,' but Republicans could support Facebook suit
05/06/20 China Renaissance
Twitter price target lowered to $23 from $25 at China Renaissance
MSFT Microsoft
$183.30 /

+2.06 (+1.14%)

05/28/20 Needham
Workday price target raised to $200 from $175 at Needham
05/27/20 Summit Insights
Microsoft initiated with a Buy at Summit Insights
05/18/20 RBC Capital
Microsoft price target raised to $200 from $196 at RBC Capital
05/15/20 Morgan Stanley
Security another large market opportunity for Microsoft, says Morgan Stanley
GOOG Alphabet
$1,430.80 /

+14.43 (+1.02%)

05/12/20 Citi
Alphabet price target raised to $1,600 from $1,400 at Citi
05/07/20 Credit Suisse
YouTube TV deal 'the big news' from ViacomCBS report, says Credit Suisse
GOOGL Alphabet Class A
$1,435.82 /

+17.61 (+1.24%)

FB Facebook
$223.10 /

-2.04 (-0.91%)

05/27/20 Citi
Facebook price target raised to $275 from $245 at Citi
COTY Coty
$3.63 /

-0.56 (-13.38%)

05/13/20 Exane BNP Paribas
Coty downgraded to Neutral from Outperform at Exane BNP Paribas
05/13/20 Exane BNP Paribas
Coty downgraded to Neutral from Outperform at Exane BNP Paribas
05/12/20 Deutsche Bank
Coty price target lowered to $6 from $8 at Deutsche Bank
04/27/20
Coty cut to Neutral at DA Davidson on valuation
SAVE Spirit Airlines
$12.96 /

+0.035 (+0.27%)

05/29/20 Wolfe Research
Spirit Airlines downgraded to Underperform from Peer Perform at Wolfe Research
05/18/20 Evercore ISI
Spirit Airlines upgraded to Outperform from In Line at Evercore ISI
05/13/20
Fly Intel: Top five analyst downgrades
05/13/20 Raymond James
Spirit Airlines downgraded to Market Perform from Outperform at Raymond James
LUV Southwest
$32.11 /

-0.44 (-1.35%)

05/26/20
Fly Intel: Top five analyst upgrades
05/26/20 UBS
Southwest upgraded to Buy from Neutral at UBS
05/19/20 Goldman Sachs
Southwest, United seeing modest improvements in demand, says Goldman Sachs
05/04/20 Barclays
Barclays downgrades U.S. Airlines sector along with American and Delta
DAL Delta Air Lines
$25.19 /

-0.47 (-1.83%)

05/04/20 Barclays
Delta Air Lines downgraded to Equal Weight from Overweight at Barclays
04/23/20 Raymond James
Delta Air Lines price target lowered to $36 from $40 at Raymond James
04/21/20 Deutsche Bank
Delta Air Lines price target lowered to $47 from $51 at Deutsche Bank
STAY Extended Stay America
$11.50 /

+0.17 (+1.50%)

04/22/20
Fly Intel: Top five analyst upgrades
04/22/20 BofA
Choice Hotels upgraded to Neutral from Underperform at Bofa
04/22/20 Jefferies
Jefferies upgrades Extended Stay America to Buy, doubles price target to $14
04/22/20 Jefferies
Extended Stay America upgraded to Buy from Hold at Jefferies
LIND Lindblad Expeditions
$7.87 /

+0.2 (+2.61%)

04/28/20 Stifel
Lindblad demand should return faster than 'normal' cruises, says Stifel
04/22/20 Deutsche Bank
Lindblad Expeditions price target lowered to $7 from $16 at Deutsche Bank
04/13/20 Sidoti
Lindblad Expeditions downgraded to Neutral from Buy at Sidoti
03/25/20 Sidoti
Lindblad Expeditions upgraded to Buy from Neutral at Sidoti
MPC Marathon Petroleum
$35.13 /

-0.08 (-0.23%)

05/13/20 Morgan Stanley
U.S. gasoline consumption appears to have bottomed, says Morgan Stanley
04/24/20 Citi
Marathon Petroleum downgraded to Neutral from Buy at Citi
03/24/20 Raymond James
Marathon Petroleum double downgraded to Market Perform at Raymond James
03/24/20 Raymond James
Marathon Petroleum downgraded to Market Perform from Strong Buy at Raymond James
LVS Las Vegas Sands
$47.96 /

-0.62 (-1.28%)

05/21/20
Fly Intel: Top five analyst upgrades
05/21/20 Credit Suisse
Credit Suisse upgrades Las Vegas Sands to Outperform with $58 target
05/21/20 Credit Suisse
Las Vegas Sands assumed with an Outperform from Neutral at Credit Suisse
05/06/20 Roth Capital
Las Vegas Sands price target lowered to $52 from $69 at Roth Capital
CTRE CareTrust REIT
$18.62 /

-0.73 (-3.77%)

04/29/20 Raymond James
CareTrust REIT upgraded to Outperform from Market Perform at Raymond James
04/29/20 Raymond James
CareTrust REIT upgraded to Outperform from Market Perform at Raymond James
04/06/20 Mizuho
CareTrust REIT upgraded to Neutral from Underperform at Mizuho
03/11/20 Mizuho
Sabra Health Care to be pressured by coronavirus at facility, says Mizuho
VLO Valero
$66.62 /

-0.59 (-0.88%)

05/21/20 US Capital Advisors
Valero downgraded to Overweight from Buy at US Capital Advisors
05/04/20 Mizuho
Mizuho upgrades Valero, Phillips 66 and HollyFrontier to Buy from Neutral
05/04/20 Mizuho
Valero upgraded to Buy from Neutral at Mizuho
PSX Phillips 66
$78.30 /

-0.35 (-0.45%)

05/21/20 US Capital Advisors
Phillips 66 downgraded to Overweight from Buy at US Capital Advisors
05/13/20 Wolfe Research
Phillips 66 downgraded to Peer Perform from Outperform at Wolfe Research
CQP Cheniere Energy Partners
$33.91 /

+0.87 (+2.63%)

03/24/20 Barclays
Cheniere Energy Partners upgraded to Overweight from Equal Weight at Barclays
03/12/20 Credit Suisse
Cheniere Energy Partners upgraded to Neutral from Underperform at Credit Suisse
03/05/20 UBS
Cheniere Energy Partners upgraded to Buy from Neutral at UBS
02/26/20 Odeon Capital
Cheniere Energy Partners upgraded to Buy from Hold at Odeon Capital
BAESY BAE Systems
$0.00 /

+ (+0.00%)

05/18/20 UBS
BAE Systems price target lowered to 511 GBp from 700 GBp at UBS
04/29/20 JPMorgan
BAE Systems price target lowered to 765 GBp from 775 GBp at JPMorgan
04/29/20 JPMorgan
BAE Systems shares offer 50% upside potential, says JPMorgan
04/27/20 Morgan Stanley
BAE Systems upgraded to Overweight from Equal Weight at Morgan Stanley
VLO Valero
$66.62 /

-0.59 (-0.88%)

TWTR Twitter
$30.97 /

-0.63 (-1.99%)

TGT Target
$122.50 /

+4.055 (+3.42%)

STAY Extended Stay America
$11.50 /

+0.17 (+1.50%)

SAVE Spirit Airlines
$12.96 /

+0.035 (+0.27%)

PSX Phillips 66
$78.30 /

-0.35 (-0.45%)

MSFT Microsoft
$183.30 /

+2.06 (+1.14%)

MPC Marathon Petroleum
$35.13 /

-0.08 (-0.23%)

LVS Las Vegas Sands
$47.96 /

-0.62 (-1.28%)

LUV Southwest
$32.11 /

-0.44 (-1.35%)

LIND Lindblad Expeditions
$7.87 /

+0.2 (+2.61%)

GOOG Alphabet
$1,430.80 /

+14.43 (+1.02%)

FB Facebook
$223.10 /

-2.04 (-0.91%)

DAL Delta Air Lines
$25.19 /

-0.47 (-1.83%)

CTRE CareTrust REIT
$18.62 /

-0.73 (-3.77%)

CQP Cheniere Energy Partners
$33.91 /

+0.87 (+2.63%)

COTY Coty
$3.63 /

-0.56 (-13.38%)

AMZN Amazon.com
$2,442.37 /

+42.04 (+1.75%)

AMGN Amgen
$230.13 /

+6.11 (+2.73%)

ALXN Alexion
$120.03 /

+5.595 (+4.89%)

AAPL Apple
$317.94 /

-0.38 (-0.12%)

VLO Valero
$66.62 /

-0.59 (-0.88%)

TWTR Twitter
$30.97 /

-0.63 (-1.99%)

TGT Target
$122.50 /

+4.055 (+3.42%)

STAY Extended Stay America
$11.50 /

+0.17 (+1.50%)

SAVE Spirit Airlines
$12.96 /

+0.035 (+0.27%)

PSX Phillips 66
$78.30 /

-0.35 (-0.45%)

MSFT Microsoft
$183.30 /

+2.06 (+1.14%)

MPC Marathon Petroleum
$35.13 /

-0.08 (-0.23%)

LVS Las Vegas Sands
$47.96 /

-0.62 (-1.28%)

LUV Southwest
$32.11 /

-0.44 (-1.35%)

LIND Lindblad Expeditions
$7.87 /

+0.2 (+2.61%)

GOOG Alphabet
$1,430.80 /

+14.43 (+1.02%)

CTRE CareTrust REIT
$18.62 /

-0.73 (-3.77%)

CQP Cheniere Energy Partners
$33.91 /

+0.87 (+2.63%)

COTY Coty
$3.63 /

-0.56 (-13.38%)

BAESY BAE Systems
$0.00 /

+ (+0.00%)

AMZN Amazon.com
$2,442.37 /

+42.04 (+1.75%)

AMGN Amgen
$230.13 /

+6.11 (+2.73%)

ALXN Alexion
$120.03 /

+5.595 (+4.89%)

AAPL Apple
$317.94 /

-0.38 (-0.12%)

TWTR Twitter
$30.97 /

-0.63 (-1.99%)

TGT Target
$122.50 /

+4.055 (+3.42%)

STAY Extended Stay America
$11.50 /

+0.17 (+1.50%)

SAVE Spirit Airlines
$12.96 /

+0.035 (+0.27%)

MSFT Microsoft
$183.30 /

+2.06 (+1.14%)

MPC Marathon Petroleum
$35.13 /

-0.08 (-0.23%)

LVS Las Vegas Sands
$47.96 /

-0.62 (-1.28%)

LUV Southwest
$32.11 /

-0.44 (-1.35%)

DAL Delta Air Lines
$25.19 /

-0.47 (-1.83%)

CQP Cheniere Energy Partners
$33.91 /

+0.87 (+2.63%)

COTY Coty
$3.63 /

-0.56 (-13.38%)

BAESY BAE Systems
$0.00 /

+ (+0.00%)

AMZN Amazon.com
$2,442.37 /

+42.04 (+1.75%)

AMGN Amgen
$230.13 /

+6.11 (+2.73%)

ALXN Alexion
$120.03 /

+5.595 (+4.89%)

AAPL Apple
$317.94 /

-0.38 (-0.12%)

VLO Valero
$66.62 /

-0.59 (-0.88%)

TWTR Twitter
$30.97 /

-0.63 (-1.99%)

TGT Target
$122.50 /

+4.055 (+3.42%)

SAVE Spirit Airlines
$12.96 /

+0.035 (+0.27%)

PSX Phillips 66
$78.30 /

-0.35 (-0.45%)

MSFT Microsoft
$183.30 /

+2.06 (+1.14%)

MPC Marathon Petroleum
$35.13 /

-0.08 (-0.23%)

LVS Las Vegas Sands
$47.96 /

-0.62 (-1.28%)

LUV Southwest
$32.11 /

-0.44 (-1.35%)

GOOGL Alphabet Class A
$1,435.82 /

+17.61 (+1.24%)

GOOG Alphabet
$1,430.80 /

+14.43 (+1.02%)

FB Facebook
$223.10 /

-2.04 (-0.91%)

DAL Delta Air Lines
$25.19 /

-0.47 (-1.83%)

COTY Coty
$3.63 /

-0.56 (-13.38%)

AMZN Amazon.com
$2,442.37 /

+42.04 (+1.75%)

ALXN Alexion
$120.03 /

+5.595 (+4.89%)

AAPL Apple
$317.94 /

-0.38 (-0.12%)

GOOG Alphabet
$1,430.80 /

+14.43 (+1.02%)

AMZN Amazon.com
$2,442.37 /

+42.04 (+1.75%)

AAPL Apple
$317.94 /

-0.38 (-0.12%)

Hot Stocks
Alexion, Amgen reach settlement deal on patent challenge » 16:37
05/31/20
05/31
16:37
05/31/20
16:37
ALXN

Alexion

$120.03 /

+5.595 (+4.89%)

, AMGN

Amgen

$230.13 /

+6.11 (+2.73%)

According to a…

According to a company's filing, "On May 28, 2020, Alexion Pharmaceuticals [ALXN] and Amgen [AMGN] entered into a Confidential Settlement and License Agreement to settle three inter partes review proceedings at the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office initiated by Amgen that the Company previously disclosed. Pursuant to the Settlement Agreement, the company and Amgen have agreed to file a motion with the PTAB to terminate each of the pending IPRs. In addition, effective March 1, 2025 (or an earlier date in certain circumstances), the company grants to Amgen (and its affiliates and certain partners) a non-exclusive, royalty-free, license under U.S. patents and patent applications related to eculizumab and various aspects of the eculizumab product that the company currently markets and sells under the tradename SOLIRIS. This license will allow Amgen (and its affiliates and certain partners), effective March 1, 2025, the right to make, have made, use, import, have imported, sell, have sold, offer for sale, have offered for sale, distribute, and have distributed in or for the U.S., an eculizumab product." The foregoing description of the Settlement Agreement does not purport to be complete and is qualified in its entirety by reference to the Settlement Agreement, which the Company intends to file as an exhibit to a future current or periodic report.

ShowHide Related Items >><<
AMGN Amgen
$230.13 /

+6.11 (+2.73%)

ALXN Alexion
$120.03 /

+5.595 (+4.89%)

ALXN Alexion
$120.03 /

+5.595 (+4.89%)

05/28/20 Raymond James
Raymond James keeps Outperform on Alexion after IP settlement analysis
05/28/20 Piper Sandler
Alexion settlement could 'clear the deck' for acquirer, says Piper Sandler
05/28/20 Cowen
Alexion settlement may yield upside surprise, says Cowen
05/28/20 Stifel
Alexion, Amgen appear to have agreed to settlement deal, says Stifel
AMGN Amgen
$230.13 /

+6.11 (+2.73%)

05/22/20 Piper Sandler
Harpoon Therapeutics initiated with an Overweight at Piper Sandler
AMGN Amgen
$230.13 /

+6.11 (+2.73%)

ALXN Alexion
$120.03 /

+5.595 (+4.89%)

AMGN Amgen
$230.13 /

+6.11 (+2.73%)

ALXN Alexion
$120.03 /

+5.595 (+4.89%)

AMGN Amgen
$230.13 /

+6.11 (+2.73%)

ALXN Alexion
$120.03 /

+5.595 (+4.89%)

ALXN Alexion
$120.03 /

+5.595 (+4.89%)

Conference/Events
American Society of Clinical Oncology (ASCO) to hold virtual meeting » 04:55
05/31/20
05/31
04:55
05/31/20
04:55
ABBV

AbbVie

$92.78 /

+2.77 (+3.08%)

, ALLO

Allogene Therapeutics

$48.08 /

+1.48 (+3.18%)

, AMGN

Amgen

$230.13 /

+6.11 (+2.73%)

, ATNX

Athenex

$10.91 /

-0.21 (-1.89%)

, AVEO

Aveo Pharmaceuticals

$8.14 /

-1.08 (-11.71%)

, AZN

AstraZeneca

$54.60 /

+1.1 (+2.06%)

, BCYC

Bicycle Therapeutics

$17.50 /

-0.785 (-4.29%)

, BLUE

Bluebird Bio

$63.63 /

+2.82 (+4.64%)

, BPMC

Blueprint Medicines

$65.16 /

-1.84 (-2.75%)

, CGEN

Compugen

$15.50 /

+3.13 (+25.30%)

, HALO

Halozyme

$24.26 /

+0.79 (+3.37%)

, EXEL

Exelixis

$24.68 /

+0.35 (+1.44%)

, DCPH

Deciphera

$58.47 /

+1.53 (+2.69%)

, KURA

Kura Oncology

$17.09 /

+0.38 (+2.27%)

, KPTI

Karyopharm

$18.49 /

-0.31 (-1.65%)

, MRK

Merck

$80.85 /

+1.83 (+2.32%)

, BMY

Bristol-Myers

$59.72 /

-0.08 (-0.13%)

, MRSN

Mersana Therapeutics

$22.55 /

+2.85 (+14.47%)

, NXTC

NextCure

$31.20 /

-1.96 (-5.91%)

, PFE

Pfizer

$38.14 /

-0.03 (-0.08%)

, RECN

Changed to RGP

$0.00 /

+ (+0.00%)

, REPL

Replimune Group

$18.85 /

+0.3 (+1.62%)

, SBPH

Spring Bank Pharmaceuticals

$1.66 /

+0.015 (+0.91%)

, SGEN

Seattle Genetics

$157.30 /

+5.53 (+3.64%)

, STML

Stemline

$11.89 /

+ (+0.00%)

, SYRS

Syros Pharmaceuticals

$9.77 /

+0.25 (+2.63%)

, TRIL

Trillium Therapeutics

$6.76 /

+0.995 (+17.26%)

, TROV

Changed name to CRDF

$0.00 /

+ (+0.00%)

, XNCR

Xencor

$30.30 /

-0.69 (-2.23%)

Virtual Annual Meeting of…

Virtual Annual Meeting of ASCO 2020 will be held on May 29-31. Webcast Link

ShowHide Related Items >><<
XNCR Xencor
$30.30 /

-0.69 (-2.23%)

TROV Changed name to CRDF
$0.00 /

+ (+0.00%)

TRIL Trillium Therapeutics
$6.76 /

+0.995 (+17.26%)

SYRS Syros Pharmaceuticals
$9.77 /

+0.25 (+2.63%)

STML Stemline
$11.89 /

+ (+0.00%)

SGEN Seattle Genetics
$157.30 /

+5.53 (+3.64%)

SBPH Spring Bank Pharmaceuticals
$1.66 /

+0.015 (+0.91%)

REPL Replimune Group
$18.85 /

+0.3 (+1.62%)

RECN Changed to RGP
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.14 /

-0.03 (-0.08%)

NXTC NextCure
$31.20 /

-1.96 (-5.91%)

MRSN Mersana Therapeutics
$22.55 /

+2.85 (+14.47%)

MRK Merck
$80.85 /

+1.83 (+2.32%)

KURA Kura Oncology
$17.09 /

+0.38 (+2.27%)

KPTI Karyopharm
$18.49 /

-0.31 (-1.65%)

HALO Halozyme
$24.26 /

+0.79 (+3.37%)

EXEL Exelixis
$24.68 /

+0.35 (+1.44%)

DCPH Deciphera
$58.47 /

+1.53 (+2.69%)

CGEN Compugen
$15.50 /

+3.13 (+25.30%)

BPMC Blueprint Medicines
$65.16 /

-1.84 (-2.75%)

BMY Bristol-Myers
$59.72 /

-0.08 (-0.13%)

BLUE Bluebird Bio
$63.63 /

+2.82 (+4.64%)

BCYC Bicycle Therapeutics
$17.50 /

-0.785 (-4.29%)

AZN AstraZeneca
$54.60 /

+1.1 (+2.06%)

AVEO Aveo Pharmaceuticals
$8.14 /

-1.08 (-11.71%)

ATNX Athenex
$10.91 /

-0.21 (-1.89%)

AMGN Amgen
$230.13 /

+6.11 (+2.73%)

ALLO Allogene Therapeutics
$48.08 /

+1.48 (+3.18%)

ABBV AbbVie
$92.78 /

+2.77 (+3.08%)

ABBV AbbVie
$92.78 /

+2.77 (+3.08%)

05/22/20 Piper Sandler
Growth of Biohaven's Nurtec continues to beat AbbVie's Ubrelvy, says Piper
05/21/20 Piper Sandler
Piper Sandler remains Overweight on Synlogic after AbbVie ends collaboration
05/18/20 BofA
AbbVie reinstated with a Neutral at BofA
05/12/20 JPMorgan
AbbVie resumed with an Overweight from Neutral at JPMorgan
ALLO Allogene Therapeutics
$48.08 /

+1.48 (+3.18%)

05/29/20 H.C. Wainwright
Allogene Therapeutics price target raised to $55 from $42 at H.C. Wainwright
05/29/20 Piper Sandler
Allogene Therapeutics price target raised to $70 from $50 at Piper Sandler
05/19/20 Roth Capital
Allogene Therapeutics upgraded to Buy with $60 target at Roth Capital
05/19/20 Roth Capital
Allogene Therapeutics upgraded to Buy from Neutral at Roth Capital
AMGN Amgen
$230.13 /

+6.11 (+2.73%)

05/28/20 Piper Sandler
Alexion settlement could 'clear the deck' for acquirer, says Piper Sandler
05/28/20 Cowen
Alexion settlement may yield upside surprise, says Cowen
05/28/20 Stifel
Alexion, Amgen appear to have agreed to settlement deal, says Stifel
05/22/20 Piper Sandler
Harpoon Therapeutics initiated with an Overweight at Piper Sandler
ATNX Athenex
$10.91 /

-0.21 (-1.89%)

12/13/19 RBC Capital
Athenex oraxol OS and ORR a 'best case,' buy on weakness, says RBC Capital
12/06/19 SunTrust
Athenex initiated with a Buy at SunTrust
11/19/19 RBC Capital
Athenex gets 'third SABCS win' ahead of meeting, says RBC Capital
08/07/19 RBC Capital
Athenex's Oraxol data 'near best-case,' says RBC Capital
AVEO Aveo Pharmaceuticals
$8.14 /

-1.08 (-11.71%)

05/29/20 Piper Sandler
Aveo Pharmaceuticals price target raised to $26 from $18.50 at Piper Sandler
05/29/20 Baird
Aveo Pharmaceuticals price target raised to $24 from $15 at Baird
05/01/20 H.C. Wainwright
Aveo Pharmaceuticals price target raised to $10 from $6 at H.C. Wainwright
04/01/20 H.C. Wainwright
Aveo Pharmaceuticals price target raised to $6 from $4 at H.C. Wainwright
AZN AstraZeneca
$54.60 /

+1.1 (+2.06%)

05/29/20 Guggenheim
AstraZeneca price target raised to 10,100 GBp from 9,100 GBp at Guggenheim
05/14/20 Evercore ISI
Evercore ISI says paper 'generally supportive' of AstraZeneca COVID vaccine
05/06/20 Morgan Stanley
AstraZeneca price target raised to 8,630 GBp from 8,600 GBp at Morgan Stanley
05/04/20 Citi
Citi opens 'positive catalyst watch' on AstraZeneca
BCYC Bicycle Therapeutics
$17.50 /

-0.785 (-4.29%)

04/17/20
Fly Intel: Top five analyst initiations
04/17/20 H.C. Wainwright
Bicycle Therapeutics initiated with a Buy at H.C. Wainwright
04/07/20 Piper Sandler
Bicycle Therapeutics' timelines to be impacted by COVID-19, says Piper Sandler
02/25/20 Piper Sandler
Bicycle Therapeutics price target raised to $30 from $20 at Piper Sandler
BLUE Bluebird Bio
$63.63 /

+2.82 (+4.64%)

05/13/20 Stifel
Bluebird's ide-cel remains approvable despite FDA's 'strict stance,' says Stifel
05/13/20 Piper Sandler
Bluebird should be able to easily address RTF issues, says Piper Sandler
05/12/20 RBC Capital
Bluebird Bio initiated with an Outperform at RBC Capital
05/12/20 Oppenheimer
Bluebird Bio price target lowered to $111 from $122 at Oppenheimer
BPMC Blueprint Medicines
$65.16 /

-1.84 (-2.75%)

05/29/20 Raymond James
Blueprint approval for pralsetinib could come before PDUFA, says Raymond James
05/06/20 Nomura Instinet
Deciphera downgraded to Neutral on GIST program risks at Nomura Instinet
05/05/20 Barclays
Blueprint Medicines initiated with an Equal Weight at Barclays
04/29/20 SVB Leerink
Deciphera price target raised to $55 from $50 at SVB Leerink
CGEN Compugen
$15.50 /

+3.13 (+25.30%)

05/26/20 JMP Securities
Compugen resumed with an Outperform at JMP Securities
05/13/20
Fly Intel: Top five analyst initiations
05/13/20 Stifel
Compugen initiated with a Buy at Stifel
05/07/20
Fly Intel: Top five analyst initiations
HALO Halozyme
$24.26 /

+0.79 (+3.37%)

05/26/20 Piper Sandler
Halozyme's Enhanze business nearing accelerated growth, says Piper Sandler
05/12/20 JMP Securities
Halozyme price target raised to $34 from $24 at JMP Securities
05/04/20 Cantor Fitzgerald
Halozyme price target raised to $39 from $35 at Cantor Fitzgerald
03/23/20 Citi
Sarepta, DBV among Citi's SMid Biotech picks amid coronavirus outbreak
EXEL Exelixis
$24.68 /

+0.35 (+1.44%)

05/14/20 SunTrust
Exelixis price target raised to $40 from $35 at SunTrust
05/13/20 Piper Sandler
Exelixis mCRPC data for CABOMETYX may accelerate approval, says Piper Sandler
05/06/20 Piper Sandler
Exelixis price target raised to $30 from $23 at Piper Sandler
04/21/20 Guggenheim
Exelixis price target raised to $32 from $27 at Guggenheim
DCPH Deciphera
$58.47 /

+1.53 (+2.69%)

05/18/20 SunTrust
Deciphera price target raised to $91 from $82 at SunTrust
05/18/20 Barclays
Deciphera price target raised to $85 from $80 at Barclays
05/18/20 Piper Sandler
Piper Sandler a buyer of Deciphera shares on the open
05/15/20 Piper Sandler
Deciphera's Ripretinib approved 3 months ahead of schedule, says Piper Sandler
KURA Kura Oncology
$17.09 /

+0.38 (+2.27%)

05/29/20 Piper Sandler
Kura's tipifarnib updates support tumor agnostic potential, says Piper Sandler
05/29/20 H.C. Wainwright
Kura data 'solidifying' confidence in AIM-HN study, says H.C. Wainwright
05/19/20 Deutsche Bank
Kura Oncology price target lowered to $24 from $28 at Deutsche Bank
05/06/20 Wedbush
Kura prioritizing development of tipifarnib for HRAS-HNSCC, says Wedbush
KPTI Karyopharm
$18.49 /

-0.31 (-1.65%)

05/06/20 H.C. Wainwright
Karyopharm price target lowered to $40 from $43 at H.C. Wainwright
04/07/20 Wedbush
Wedbush sees signs of 'potential utility' for Karyopharm's selinexor for COVID
04/07/20 H.C. Wainwright
XPO1 inhibitors have shown promise as COVID-19 treatment, says H.C. Wainwright
03/04/20 Barclays
Karyopharm initiated with an Overweight at Barclays
MRK Merck
$80.85 /

+1.83 (+2.32%)

05/27/20 Alliance Global Partners
PDS Biotechnology initiated with a Buy at Alliance Global Partners
05/20/20 JonesTrading
Merck collaboration positions Surface Oncology well, says JonesTrading
04/27/20 SVB Leerink
Clovis downgraded to Underperform at SVB Leerink as prostate opportunity fades
04/06/20 Raymond James
NGM Biopharmaceuticals initiated with a Strong Buy at Raymond James
BMY Bristol-Myers
$59.72 /

-0.08 (-0.13%)

04/20/20 Piper Sandler
Exelixis combo approval would increase kidney cancer use, says Piper Sandler
MRSN Mersana Therapeutics
$22.55 /

+2.85 (+14.47%)

05/27/20 H.C. Wainwright
Mersana Therapeutics price target raised to $26 from $13 at H.C. Wainwright
04/29/20 BTIG
Mersana Therapeutics initiated with a Buy at BTIG
01/21/20 H.C. Wainwright
Mersana Therapeutics price target raised to $12 from $7 at H.C. Wainwright
08/20/19 H.C. Wainwright
H.C. Wainwright says trial initiation at higher dosing 'bodes well' for Mersana
NXTC NextCure
$31.20 /

-1.96 (-5.91%)

05/29/20 Piper Sandler
NextCure data shows S15-mediated activity, says Piper Sandler
05/26/20 JMP Securities
NextCure initiated with an Outperform at JMP Securities
04/13/20 Piper Sandler
NextCure could report Phase I biomarker data at ASCO, says Piper Sandler
03/24/20 Benchmark
NextCure initiated with a Buy at Benchmark
PFE Pfizer
$38.14 /

-0.03 (-0.08%)

05/21/20 Piper Sandler
Gilead's filgotinib likely being underestimated by Street, says Piper Sandler
05/19/20 H.C. Wainwright
BioNTech upgraded to Buy from Neutral at H.C. Wainwright
05/15/20 Goldman Sachs
After Pfizer data, Goldman says Sarepta remains 'leader' in DMD gene therapy
05/15/20 JPMorgan
JPMorgan still sees Sarepta in pole position in DMD space
RECN Changed to RGP
$0.00 /

+ (+0.00%)

01/03/20 Baird
Resources Connection Q3 guidance 'materially below' expectations, says Baird
10/03/19 JPMorgan
Resources Connection near-term outlook remains challenged, says JPMorgan
REPL Replimune Group
$18.85 /

+0.3 (+1.62%)

05/05/20 Barclays
Replimune Group initiated with an Overweight at Barclays
03/25/20 Wedbush
Replimune Group added to Best Ideas List at Wedbush
11/11/19 Roth Capital
Replimune Group price target raised to $30 from $20 at Roth Capital
09/04/19 Roth Capital
Replimune Group initiated with a Buy at Roth Capital
SBPH Spring Bank Pharmaceuticals
$1.66 /

+0.015 (+0.91%)

04/02/20 Piper Sandler
Piper Sandler keeps Neutral on Spring Bank as study enrollment expected to slow
01/29/20 Jefferies
Spring Bank Pharmaceuticals downgraded to Hold from Buy at Jefferies
01/29/20 Piper Sandler
Piper keeps Neutral rating on Spring Bank after inarigivir discontinued
12/30/19
Fly Intel: Top five analyst actions
SGEN Seattle Genetics
$157.30 /

+5.53 (+3.64%)

05/26/20 Goldman Sachs
Astellas Pharma upgraded to Buy on raised PADCEV estimates at Goldman Sachs
05/26/20 JMP Securities
Seattle Genetics initiated with an Outperform at JMP Securities
05/26/20 Goldman Sachs
Incyte downgraded to Buy from Conviction Buy at Goldman Sachs
05/26/20 Goldman Sachs
Seattle Genetics upgraded to Conviction Buy from Buy at Goldman Sachs
STML Stemline
$11.89 /

+ (+0.00%)

05/05/20 H.C. Wainwright
Stemline downgraded to Neutral from Buy at H.C. Wainwright
05/05/20 Ladenburg
Stemline downgraded to Neutral from Buy at Ladenburg
05/04/20 Alliance Global Partners
Stemline downgraded to Neutral from Buy at Alliance Global Partners
05/04/20 Wedbush
Stemline downgraded to Neutral from Outperform at Wedbush
SYRS Syros Pharmaceuticals
$9.77 /

+0.25 (+2.63%)

05/29/20 Roth Capital
Syros Pharmaceuticals ASCO update bodes well for ph1 data, says Roth Capital
05/29/20 Piper Sandler
Syros price target raised to $14 after ASCO update at Piper Sandler
04/23/20 JonesTrading
Syros Pharmaceuticals initiated with a Buy at JonesTrading
03/06/20 H.C. Wainwright
Syros Pharmaceuticals price target lowered to $8 from $10 at H.C. Wainwright
TRIL Trillium Therapeutics
$6.76 /

+0.995 (+17.26%)

05/26/20 JMP Securities
Trillium Therapeutics initiated with an Outperform at JMP Securities
08/19/19
Fly Intel: Top five analyst downgrades
08/19/19 H.C. Wainwright
Trillium Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
TROV Changed name to CRDF
$0.00 /

+ (+0.00%)

01/28/20 Noble Capital
Trovagene resumed with an Outperform at Noble Capital
XNCR Xencor
$30.30 /

-0.69 (-2.23%)

05/13/20 Piper Sandler
Xencor's XmAb20717 shows first-ever clinical benefit, says Piper Sandler
03/04/20 Barclays
Barclays starts small, mid cap Biotechnology sector with Positive view
03/04/20 Barclays
Xencor initiated with an Underweight at Barclays
02/25/20 Guggenheim
Xencor upgraded to Buy from Neutral at Guggenheim
XNCR Xencor
$30.30 /

-0.69 (-2.23%)

TRIL Trillium Therapeutics
$6.76 /

+0.995 (+17.26%)

SYRS Syros Pharmaceuticals
$9.77 /

+0.25 (+2.63%)

STML Stemline
$11.89 /

+ (+0.00%)

SGEN Seattle Genetics
$157.30 /

+5.53 (+3.64%)

SBPH Spring Bank Pharmaceuticals
$1.66 /

+0.015 (+0.91%)

REPL Replimune Group
$18.85 /

+0.3 (+1.62%)

RECN Changed to RGP
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.14 /

-0.03 (-0.08%)

NXTC NextCure
$31.20 /

-1.96 (-5.91%)

MRSN Mersana Therapeutics
$22.55 /

+2.85 (+14.47%)

MRK Merck
$80.85 /

+1.83 (+2.32%)

KURA Kura Oncology
$17.09 /

+0.38 (+2.27%)

KPTI Karyopharm
$18.49 /

-0.31 (-1.65%)

HALO Halozyme
$24.26 /

+0.79 (+3.37%)

EXEL Exelixis
$24.68 /

+0.35 (+1.44%)

DCPH Deciphera
$58.47 /

+1.53 (+2.69%)

CGEN Compugen
$15.50 /

+3.13 (+25.30%)

BPMC Blueprint Medicines
$65.16 /

-1.84 (-2.75%)

BMY Bristol-Myers
$59.72 /

-0.08 (-0.13%)

BLUE Bluebird Bio
$63.63 /

+2.82 (+4.64%)

BCYC Bicycle Therapeutics
$17.50 /

-0.785 (-4.29%)

AZN AstraZeneca
$54.60 /

+1.1 (+2.06%)

AVEO Aveo Pharmaceuticals
$8.14 /

-1.08 (-11.71%)

ATNX Athenex
$10.91 /

-0.21 (-1.89%)

AMGN Amgen
$230.13 /

+6.11 (+2.73%)

ALLO Allogene Therapeutics
$48.08 /

+1.48 (+3.18%)

ABBV AbbVie
$92.78 /

+2.77 (+3.08%)

TRIL Trillium Therapeutics
$6.76 /

+0.995 (+17.26%)

PFE Pfizer
$38.14 /

-0.03 (-0.08%)

MRK Merck
$80.85 /

+1.83 (+2.32%)

BMY Bristol-Myers
$59.72 /

-0.08 (-0.13%)

AZN AstraZeneca
$54.60 /

+1.1 (+2.06%)

AMGN Amgen
$230.13 /

+6.11 (+2.73%)

ABBV AbbVie
$92.78 /

+2.77 (+3.08%)

XNCR Xencor
$30.30 /

-0.69 (-2.23%)

STML Stemline
$11.89 /

+ (+0.00%)

SGEN Seattle Genetics
$157.30 /

+5.53 (+3.64%)

SBPH Spring Bank Pharmaceuticals
$1.66 /

+0.015 (+0.91%)

PFE Pfizer
$38.14 /

-0.03 (-0.08%)

MRSN Mersana Therapeutics
$22.55 /

+2.85 (+14.47%)

MRK Merck
$80.85 /

+1.83 (+2.32%)

KPTI Karyopharm
$18.49 /

-0.31 (-1.65%)

HALO Halozyme
$24.26 /

+0.79 (+3.37%)

EXEL Exelixis
$24.68 /

+0.35 (+1.44%)

DCPH Deciphera
$58.47 /

+1.53 (+2.69%)

BPMC Blueprint Medicines
$65.16 /

-1.84 (-2.75%)

BMY Bristol-Myers
$59.72 /

-0.08 (-0.13%)

BLUE Bluebird Bio
$63.63 /

+2.82 (+4.64%)

BCYC Bicycle Therapeutics
$17.50 /

-0.785 (-4.29%)

AZN AstraZeneca
$54.60 /

+1.1 (+2.06%)

AVEO Aveo Pharmaceuticals
$8.14 /

-1.08 (-11.71%)

ATNX Athenex
$10.91 /

-0.21 (-1.89%)

AMGN Amgen
$230.13 /

+6.11 (+2.73%)

ALLO Allogene Therapeutics
$48.08 /

+1.48 (+3.18%)

ABBV AbbVie
$92.78 /

+2.77 (+3.08%)

TRIL Trillium Therapeutics
$6.76 /

+0.995 (+17.26%)

RECN Changed to RGP
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.14 /

-0.03 (-0.08%)

MRSN Mersana Therapeutics
$22.55 /

+2.85 (+14.47%)

MRK Merck
$80.85 /

+1.83 (+2.32%)

EXEL Exelixis
$24.68 /

+0.35 (+1.44%)

BMY Bristol-Myers
$59.72 /

-0.08 (-0.13%)

AZN AstraZeneca
$54.60 /

+1.1 (+2.06%)

ABBV AbbVie
$92.78 /

+2.77 (+3.08%)

Conference/Events
American Society of Clinical Oncology (ASCO) to hold virtual meeting » 04:55
05/30/20
05/30
04:55
05/30/20
04:55
ABBV

AbbVie

$92.78 /

+2.77 (+3.08%)

, ALLO

Allogene Therapeutics

$48.08 /

+1.48 (+3.18%)

, AMGN

Amgen

$230.13 /

+6.11 (+2.73%)

, ATNX

Athenex

$10.91 /

-0.21 (-1.89%)

, AVEO

Aveo Pharmaceuticals

$8.14 /

-1.08 (-11.71%)

, AZN

AstraZeneca

$54.60 /

+1.1 (+2.06%)

, BCYC

Bicycle Therapeutics

$17.50 /

-0.785 (-4.29%)

, BLUE

Bluebird Bio

$63.63 /

+2.82 (+4.64%)

, BPMC

Blueprint Medicines

$65.16 /

-1.84 (-2.75%)

, CGEN

Compugen

$15.50 /

+3.13 (+25.30%)

, HALO

Halozyme

$24.26 /

+0.79 (+3.37%)

, EXEL

Exelixis

$24.68 /

+0.35 (+1.44%)

, DCPH

Deciphera

$58.47 /

+1.53 (+2.69%)

, KURA

Kura Oncology

$17.09 /

+0.38 (+2.27%)

, KPTI

Karyopharm

$18.49 /

-0.31 (-1.65%)

, MRK

Merck

$80.85 /

+1.83 (+2.32%)

, BMY

Bristol-Myers

$59.72 /

-0.08 (-0.13%)

, MRSN

Mersana Therapeutics

$22.55 /

+2.85 (+14.47%)

, NXTC

NextCure

$31.20 /

-1.96 (-5.91%)

, PFE

Pfizer

$38.14 /

-0.03 (-0.08%)

, RECN

Changed to RGP

$0.00 /

+ (+0.00%)

, REPL

Replimune Group

$18.85 /

+0.3 (+1.62%)

, SBPH

Spring Bank Pharmaceuticals

$1.66 /

+0.015 (+0.91%)

, SGEN

Seattle Genetics

$157.30 /

+5.53 (+3.64%)

, STML

Stemline

$11.89 /

+ (+0.00%)

, SYRS

Syros Pharmaceuticals

$9.77 /

+0.25 (+2.63%)

, TRIL

Trillium Therapeutics

$6.76 /

+0.995 (+17.26%)

, TROV

Changed name to CRDF

$0.00 /

+ (+0.00%)

, XNCR

Xencor

$30.30 /

-0.69 (-2.23%)

Virtual Annual Meeting of…

Virtual Annual Meeting of ASCO 2020 will be held on May 29-31. Webcast Link

ShowHide Related Items >><<
XNCR Xencor
$30.30 /

-0.69 (-2.23%)

TROV Changed name to CRDF
$0.00 /

+ (+0.00%)

TRIL Trillium Therapeutics
$6.76 /

+0.995 (+17.26%)

SYRS Syros Pharmaceuticals
$9.77 /

+0.25 (+2.63%)

STML Stemline
$11.89 /

+ (+0.00%)

SGEN Seattle Genetics
$157.30 /

+5.53 (+3.64%)

SBPH Spring Bank Pharmaceuticals
$1.66 /

+0.015 (+0.91%)

REPL Replimune Group
$18.85 /

+0.3 (+1.62%)

RECN Changed to RGP
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.14 /

-0.03 (-0.08%)

NXTC NextCure
$31.20 /

-1.96 (-5.91%)

MRSN Mersana Therapeutics
$22.55 /

+2.85 (+14.47%)

MRK Merck
$80.85 /

+1.83 (+2.32%)

KURA Kura Oncology
$17.09 /

+0.38 (+2.27%)

KPTI Karyopharm
$18.49 /

-0.31 (-1.65%)

HALO Halozyme
$24.26 /

+0.79 (+3.37%)

EXEL Exelixis
$24.68 /

+0.35 (+1.44%)

DCPH Deciphera
$58.47 /

+1.53 (+2.69%)

CGEN Compugen
$15.50 /

+3.13 (+25.30%)

BPMC Blueprint Medicines
$65.16 /

-1.84 (-2.75%)

BMY Bristol-Myers
$59.72 /

-0.08 (-0.13%)

BLUE Bluebird Bio
$63.63 /

+2.82 (+4.64%)

BCYC Bicycle Therapeutics
$17.50 /

-0.785 (-4.29%)

AZN AstraZeneca
$54.60 /

+1.1 (+2.06%)

AVEO Aveo Pharmaceuticals
$8.14 /

-1.08 (-11.71%)

ATNX Athenex
$10.91 /

-0.21 (-1.89%)

AMGN Amgen
$230.13 /

+6.11 (+2.73%)

ALLO Allogene Therapeutics
$48.08 /

+1.48 (+3.18%)

ABBV AbbVie
$92.78 /

+2.77 (+3.08%)

ABBV AbbVie
$92.78 /

+2.77 (+3.08%)

05/22/20 Piper Sandler
Growth of Biohaven's Nurtec continues to beat AbbVie's Ubrelvy, says Piper
05/21/20 Piper Sandler
Piper Sandler remains Overweight on Synlogic after AbbVie ends collaboration
05/18/20 BofA
AbbVie reinstated with a Neutral at BofA
05/12/20 JPMorgan
AbbVie resumed with an Overweight from Neutral at JPMorgan
ALLO Allogene Therapeutics
$48.08 /

+1.48 (+3.18%)

05/29/20 H.C. Wainwright
Allogene Therapeutics price target raised to $55 from $42 at H.C. Wainwright
05/29/20 Piper Sandler
Allogene Therapeutics price target raised to $70 from $50 at Piper Sandler
05/19/20 Roth Capital
Allogene Therapeutics upgraded to Buy with $60 target at Roth Capital
05/19/20 Roth Capital
Allogene Therapeutics upgraded to Buy from Neutral at Roth Capital
AMGN Amgen
$230.13 /

+6.11 (+2.73%)

05/28/20 Piper Sandler
Alexion settlement could 'clear the deck' for acquirer, says Piper Sandler
05/28/20 Cowen
Alexion settlement may yield upside surprise, says Cowen
05/28/20 Stifel
Alexion, Amgen appear to have agreed to settlement deal, says Stifel
05/22/20 Piper Sandler
Harpoon Therapeutics initiated with an Overweight at Piper Sandler
ATNX Athenex
$10.91 /

-0.21 (-1.89%)

12/13/19 RBC Capital
Athenex oraxol OS and ORR a 'best case,' buy on weakness, says RBC Capital
12/06/19 SunTrust
Athenex initiated with a Buy at SunTrust
11/19/19 RBC Capital
Athenex gets 'third SABCS win' ahead of meeting, says RBC Capital
08/07/19 RBC Capital
Athenex's Oraxol data 'near best-case,' says RBC Capital
AVEO Aveo Pharmaceuticals
$8.14 /

-1.08 (-11.71%)

05/29/20 Piper Sandler
Aveo Pharmaceuticals price target raised to $26 from $18.50 at Piper Sandler
05/29/20 Baird
Aveo Pharmaceuticals price target raised to $24 from $15 at Baird
05/01/20 H.C. Wainwright
Aveo Pharmaceuticals price target raised to $10 from $6 at H.C. Wainwright
04/01/20 H.C. Wainwright
Aveo Pharmaceuticals price target raised to $6 from $4 at H.C. Wainwright
AZN AstraZeneca
$54.60 /

+1.1 (+2.06%)

05/29/20 Guggenheim
AstraZeneca price target raised to 10,100 GBp from 9,100 GBp at Guggenheim
05/14/20 Evercore ISI
Evercore ISI says paper 'generally supportive' of AstraZeneca COVID vaccine
05/06/20 Morgan Stanley
AstraZeneca price target raised to 8,630 GBp from 8,600 GBp at Morgan Stanley
05/04/20 Citi
Citi opens 'positive catalyst watch' on AstraZeneca
BCYC Bicycle Therapeutics
$17.50 /

-0.785 (-4.29%)

04/17/20
Fly Intel: Top five analyst initiations
04/17/20 H.C. Wainwright
Bicycle Therapeutics initiated with a Buy at H.C. Wainwright
04/07/20 Piper Sandler
Bicycle Therapeutics' timelines to be impacted by COVID-19, says Piper Sandler
02/25/20 Piper Sandler
Bicycle Therapeutics price target raised to $30 from $20 at Piper Sandler
BLUE Bluebird Bio
$63.63 /

+2.82 (+4.64%)

05/13/20 Stifel
Bluebird's ide-cel remains approvable despite FDA's 'strict stance,' says Stifel
05/13/20 Piper Sandler
Bluebird should be able to easily address RTF issues, says Piper Sandler
05/12/20 RBC Capital
Bluebird Bio initiated with an Outperform at RBC Capital
05/12/20 Oppenheimer
Bluebird Bio price target lowered to $111 from $122 at Oppenheimer
BPMC Blueprint Medicines
$65.16 /

-1.84 (-2.75%)

05/29/20 Raymond James
Blueprint approval for pralsetinib could come before PDUFA, says Raymond James
05/06/20 Nomura Instinet
Deciphera downgraded to Neutral on GIST program risks at Nomura Instinet
05/05/20 Barclays
Blueprint Medicines initiated with an Equal Weight at Barclays
04/29/20 SVB Leerink
Deciphera price target raised to $55 from $50 at SVB Leerink
CGEN Compugen
$15.50 /

+3.13 (+25.30%)

05/26/20 JMP Securities
Compugen resumed with an Outperform at JMP Securities
05/13/20
Fly Intel: Top five analyst initiations
05/13/20 Stifel
Compugen initiated with a Buy at Stifel
05/07/20
Fly Intel: Top five analyst initiations
HALO Halozyme
$24.26 /

+0.79 (+3.37%)

05/26/20 Piper Sandler
Halozyme's Enhanze business nearing accelerated growth, says Piper Sandler
05/12/20 JMP Securities
Halozyme price target raised to $34 from $24 at JMP Securities
05/04/20 Cantor Fitzgerald
Halozyme price target raised to $39 from $35 at Cantor Fitzgerald
03/23/20 Citi
Sarepta, DBV among Citi's SMid Biotech picks amid coronavirus outbreak
EXEL Exelixis
$24.68 /

+0.35 (+1.44%)

05/14/20 SunTrust
Exelixis price target raised to $40 from $35 at SunTrust
05/13/20 Piper Sandler
Exelixis mCRPC data for CABOMETYX may accelerate approval, says Piper Sandler
05/06/20 Piper Sandler
Exelixis price target raised to $30 from $23 at Piper Sandler
04/21/20 Guggenheim
Exelixis price target raised to $32 from $27 at Guggenheim
DCPH Deciphera
$58.47 /

+1.53 (+2.69%)

05/18/20 SunTrust
Deciphera price target raised to $91 from $82 at SunTrust
05/18/20 Barclays
Deciphera price target raised to $85 from $80 at Barclays
05/18/20 Piper Sandler
Piper Sandler a buyer of Deciphera shares on the open
05/15/20 Piper Sandler
Deciphera's Ripretinib approved 3 months ahead of schedule, says Piper Sandler
KURA Kura Oncology
$17.09 /

+0.38 (+2.27%)

05/29/20 Piper Sandler
Kura's tipifarnib updates support tumor agnostic potential, says Piper Sandler
05/29/20 H.C. Wainwright
Kura data 'solidifying' confidence in AIM-HN study, says H.C. Wainwright
05/19/20 Deutsche Bank
Kura Oncology price target lowered to $24 from $28 at Deutsche Bank
05/06/20 Wedbush
Kura prioritizing development of tipifarnib for HRAS-HNSCC, says Wedbush
KPTI Karyopharm
$18.49 /

-0.31 (-1.65%)

05/06/20 H.C. Wainwright
Karyopharm price target lowered to $40 from $43 at H.C. Wainwright
04/07/20 Wedbush
Wedbush sees signs of 'potential utility' for Karyopharm's selinexor for COVID
04/07/20 H.C. Wainwright
XPO1 inhibitors have shown promise as COVID-19 treatment, says H.C. Wainwright
03/04/20 Barclays
Karyopharm initiated with an Overweight at Barclays
MRK Merck
$80.85 /

+1.83 (+2.32%)

05/27/20 Alliance Global Partners
PDS Biotechnology initiated with a Buy at Alliance Global Partners
05/20/20 JonesTrading
Merck collaboration positions Surface Oncology well, says JonesTrading
04/27/20 SVB Leerink
Clovis downgraded to Underperform at SVB Leerink as prostate opportunity fades
04/06/20 Raymond James
NGM Biopharmaceuticals initiated with a Strong Buy at Raymond James
BMY Bristol-Myers
$59.72 /

-0.08 (-0.13%)

04/20/20 Piper Sandler
Exelixis combo approval would increase kidney cancer use, says Piper Sandler
MRSN Mersana Therapeutics
$22.55 /

+2.85 (+14.47%)

05/27/20 H.C. Wainwright
Mersana Therapeutics price target raised to $26 from $13 at H.C. Wainwright
04/29/20 BTIG
Mersana Therapeutics initiated with a Buy at BTIG
01/21/20 H.C. Wainwright
Mersana Therapeutics price target raised to $12 from $7 at H.C. Wainwright
08/20/19 H.C. Wainwright
H.C. Wainwright says trial initiation at higher dosing 'bodes well' for Mersana
NXTC NextCure
$31.20 /

-1.96 (-5.91%)

05/29/20 Piper Sandler
NextCure data shows S15-mediated activity, says Piper Sandler
05/26/20 JMP Securities
NextCure initiated with an Outperform at JMP Securities
04/13/20 Piper Sandler
NextCure could report Phase I biomarker data at ASCO, says Piper Sandler
03/24/20 Benchmark
NextCure initiated with a Buy at Benchmark
PFE Pfizer
$38.14 /

-0.03 (-0.08%)

05/21/20 Piper Sandler
Gilead's filgotinib likely being underestimated by Street, says Piper Sandler
05/19/20 H.C. Wainwright
BioNTech upgraded to Buy from Neutral at H.C. Wainwright
05/15/20 Goldman Sachs
After Pfizer data, Goldman says Sarepta remains 'leader' in DMD gene therapy
05/15/20 JPMorgan
JPMorgan still sees Sarepta in pole position in DMD space
RECN Changed to RGP
$0.00 /

+ (+0.00%)

01/03/20 Baird
Resources Connection Q3 guidance 'materially below' expectations, says Baird
10/03/19 JPMorgan
Resources Connection near-term outlook remains challenged, says JPMorgan
REPL Replimune Group
$18.85 /

+0.3 (+1.62%)

05/05/20 Barclays
Replimune Group initiated with an Overweight at Barclays
03/25/20 Wedbush
Replimune Group added to Best Ideas List at Wedbush
11/11/19 Roth Capital
Replimune Group price target raised to $30 from $20 at Roth Capital
09/04/19 Roth Capital
Replimune Group initiated with a Buy at Roth Capital
SBPH Spring Bank Pharmaceuticals
$1.66 /

+0.015 (+0.91%)

04/02/20 Piper Sandler
Piper Sandler keeps Neutral on Spring Bank as study enrollment expected to slow
01/29/20 Jefferies
Spring Bank Pharmaceuticals downgraded to Hold from Buy at Jefferies
01/29/20 Piper Sandler
Piper keeps Neutral rating on Spring Bank after inarigivir discontinued
12/30/19
Fly Intel: Top five analyst actions
SGEN Seattle Genetics
$157.30 /

+5.53 (+3.64%)

05/26/20 Goldman Sachs
Astellas Pharma upgraded to Buy on raised PADCEV estimates at Goldman Sachs
05/26/20 JMP Securities
Seattle Genetics initiated with an Outperform at JMP Securities
05/26/20 Goldman Sachs
Incyte downgraded to Buy from Conviction Buy at Goldman Sachs
05/26/20 Goldman Sachs
Seattle Genetics upgraded to Conviction Buy from Buy at Goldman Sachs
STML Stemline
$11.89 /

+ (+0.00%)

05/05/20 H.C. Wainwright
Stemline downgraded to Neutral from Buy at H.C. Wainwright
05/05/20 Ladenburg
Stemline downgraded to Neutral from Buy at Ladenburg
05/04/20 Alliance Global Partners
Stemline downgraded to Neutral from Buy at Alliance Global Partners
05/04/20 Wedbush
Stemline downgraded to Neutral from Outperform at Wedbush
SYRS Syros Pharmaceuticals
$9.77 /

+0.25 (+2.63%)

05/29/20 Roth Capital
Syros Pharmaceuticals ASCO update bodes well for ph1 data, says Roth Capital
05/29/20 Piper Sandler
Syros price target raised to $14 after ASCO update at Piper Sandler
04/23/20 JonesTrading
Syros Pharmaceuticals initiated with a Buy at JonesTrading
03/06/20 H.C. Wainwright
Syros Pharmaceuticals price target lowered to $8 from $10 at H.C. Wainwright
TRIL Trillium Therapeutics
$6.76 /

+0.995 (+17.26%)

05/26/20 JMP Securities
Trillium Therapeutics initiated with an Outperform at JMP Securities
08/19/19
Fly Intel: Top five analyst downgrades
08/19/19 H.C. Wainwright
Trillium Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
TROV Changed name to CRDF
$0.00 /

+ (+0.00%)

01/28/20 Noble Capital
Trovagene resumed with an Outperform at Noble Capital
XNCR Xencor
$30.30 /

-0.69 (-2.23%)

05/13/20 Piper Sandler
Xencor's XmAb20717 shows first-ever clinical benefit, says Piper Sandler
03/04/20 Barclays
Barclays starts small, mid cap Biotechnology sector with Positive view
03/04/20 Barclays
Xencor initiated with an Underweight at Barclays
02/25/20 Guggenheim
Xencor upgraded to Buy from Neutral at Guggenheim
XNCR Xencor
$30.30 /

-0.69 (-2.23%)

TRIL Trillium Therapeutics
$6.76 /

+0.995 (+17.26%)

SYRS Syros Pharmaceuticals
$9.77 /

+0.25 (+2.63%)

STML Stemline
$11.89 /

+ (+0.00%)

SGEN Seattle Genetics
$157.30 /

+5.53 (+3.64%)

SBPH Spring Bank Pharmaceuticals
$1.66 /

+0.015 (+0.91%)

REPL Replimune Group
$18.85 /

+0.3 (+1.62%)

RECN Changed to RGP
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.14 /

-0.03 (-0.08%)

NXTC NextCure
$31.20 /

-1.96 (-5.91%)

MRSN Mersana Therapeutics
$22.55 /

+2.85 (+14.47%)

MRK Merck
$80.85 /

+1.83 (+2.32%)

KURA Kura Oncology
$17.09 /

+0.38 (+2.27%)

KPTI Karyopharm
$18.49 /

-0.31 (-1.65%)

HALO Halozyme
$24.26 /

+0.79 (+3.37%)

EXEL Exelixis
$24.68 /

+0.35 (+1.44%)

DCPH Deciphera
$58.47 /

+1.53 (+2.69%)

CGEN Compugen
$15.50 /

+3.13 (+25.30%)

BPMC Blueprint Medicines
$65.16 /

-1.84 (-2.75%)

BMY Bristol-Myers
$59.72 /

-0.08 (-0.13%)

BLUE Bluebird Bio
$63.63 /

+2.82 (+4.64%)

BCYC Bicycle Therapeutics
$17.50 /

-0.785 (-4.29%)

AZN AstraZeneca
$54.60 /

+1.1 (+2.06%)

AVEO Aveo Pharmaceuticals
$8.14 /

-1.08 (-11.71%)

ATNX Athenex
$10.91 /

-0.21 (-1.89%)

AMGN Amgen
$230.13 /

+6.11 (+2.73%)

ALLO Allogene Therapeutics
$48.08 /

+1.48 (+3.18%)

ABBV AbbVie
$92.78 /

+2.77 (+3.08%)

  • 29
    May
TRIL Trillium Therapeutics
$6.76 /

+0.995 (+17.26%)

PFE Pfizer
$38.14 /

-0.03 (-0.08%)

MRK Merck
$80.85 /

+1.83 (+2.32%)

BMY Bristol-Myers
$59.72 /

-0.08 (-0.13%)

AZN AstraZeneca
$54.60 /

+1.1 (+2.06%)

AMGN Amgen
$230.13 /

+6.11 (+2.73%)

ABBV AbbVie
$92.78 /

+2.77 (+3.08%)

XNCR Xencor
$30.30 /

-0.69 (-2.23%)

STML Stemline
$11.89 /

+ (+0.00%)

SGEN Seattle Genetics
$157.30 /

+5.53 (+3.64%)

SBPH Spring Bank Pharmaceuticals
$1.66 /

+0.015 (+0.91%)

PFE Pfizer
$38.14 /

-0.03 (-0.08%)

MRSN Mersana Therapeutics
$22.55 /

+2.85 (+14.47%)

MRK Merck
$80.85 /

+1.83 (+2.32%)

KPTI Karyopharm
$18.49 /

-0.31 (-1.65%)

HALO Halozyme
$24.26 /

+0.79 (+3.37%)

EXEL Exelixis
$24.68 /

+0.35 (+1.44%)

DCPH Deciphera
$58.47 /

+1.53 (+2.69%)

BPMC Blueprint Medicines
$65.16 /

-1.84 (-2.75%)

BMY Bristol-Myers
$59.72 /

-0.08 (-0.13%)

BLUE Bluebird Bio
$63.63 /

+2.82 (+4.64%)

BCYC Bicycle Therapeutics
$17.50 /

-0.785 (-4.29%)

AZN AstraZeneca
$54.60 /

+1.1 (+2.06%)

AVEO Aveo Pharmaceuticals
$8.14 /

-1.08 (-11.71%)

ATNX Athenex
$10.91 /

-0.21 (-1.89%)

AMGN Amgen
$230.13 /

+6.11 (+2.73%)

ALLO Allogene Therapeutics
$48.08 /

+1.48 (+3.18%)

ABBV AbbVie
$92.78 /

+2.77 (+3.08%)

TRIL Trillium Therapeutics
$6.76 /

+0.995 (+17.26%)

RECN Changed to RGP
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.14 /

-0.03 (-0.08%)

MRSN Mersana Therapeutics
$22.55 /

+2.85 (+14.47%)

MRK Merck
$80.85 /

+1.83 (+2.32%)

EXEL Exelixis
$24.68 /

+0.35 (+1.44%)

BMY Bristol-Myers
$59.72 /

-0.08 (-0.13%)

AZN AstraZeneca
$54.60 /

+1.1 (+2.06%)

ABBV AbbVie
$92.78 /

+2.77 (+3.08%)

Conference/Events
American Society of Clinical Oncology (ASCO) to hold virtual meeting » 10:14
05/29/20
05/29
10:14
05/29/20
10:14
ABBV

AbbVie

$90.97 /

+0.96 (+1.07%)

, ALLO

Allogene Therapeutics

$45.80 /

-0.8 (-1.72%)

, AMGN

Amgen

$224.10 /

+0.08 (+0.04%)

, ATNX

Athenex

$11.08 /

-0.04 (-0.36%)

, AVEO

Aveo Pharmaceuticals

$8.01 /

-1.21 (-13.12%)

, AZN

AstraZeneca

$54.97 /

+1.47 (+2.75%)

, BCYC

Bicycle Therapeutics

$18.28 /

+ (+0.00%)

, BLUE

Bluebird Bio

$61.30 /

+0.49 (+0.81%)

, BPMC

Blueprint Medicines

$66.44 /

-0.56 (-0.84%)

, CGEN

Compugen

$12.92 /

+0.55 (+4.45%)

, HALO

Halozyme

$23.49 /

+0.02 (+0.09%)

, EXEL

Exelixis

$24.46 /

+0.13 (+0.53%)

, DCPH

Deciphera

$56.95 /

+0.01 (+0.02%)

, KURA

Kura Oncology

$17.10 /

+0.39 (+2.33%)

, KPTI

Karyopharm

$18.80 /

+ (+0.00%)

, MRK

Merck

$79.24 /

+0.22 (+0.28%)

, BMY

Bristol-Myers

$60.18 /

+0.38 (+0.64%)

, MRSN

Mersana Therapeutics

$20.50 /

+0.8 (+4.06%)

, NXTC

NextCure

$32.56 /

-0.6 (-1.81%)

, PFE

Pfizer

$38.06 /

-0.11 (-0.29%)

, RECN

Changed to RGP

$0.00 /

+ (+0.00%)

, REPL

Replimune Group

$18.41 /

-0.14 (-0.75%)

, SBPH

Spring Bank Pharmaceuticals

$1.56 /

-0.085 (-5.17%)

, SGEN

Seattle Genetics

$154.34 /

+2.57 (+1.69%)

, STML

Stemline

$11.88 /

-0.01 (-0.08%)

, SYRS

Syros Pharmaceuticals

$9.43 /

-0.09 (-0.95%)

, TRIL

Trillium Therapeutics

$6.20 /

+0.435 (+7.55%)

, TROV

Changed name to CRDF

$0.00 /

+ (+0.00%)

, XNCR

Xencor

$30.45 /

-0.54 (-1.74%)

Virtual Annual Meeting of…

Virtual Annual Meeting of ASCO 2020 will be held on May 29-31. Webcast Link

ShowHide Related Items >><<
XNCR Xencor
$30.45 /

-0.54 (-1.74%)

TROV Changed name to CRDF
$0.00 /

+ (+0.00%)

TRIL Trillium Therapeutics
$6.20 /

+0.435 (+7.55%)

SYRS Syros Pharmaceuticals
$9.43 /

-0.09 (-0.95%)

STML Stemline
$11.88 /

-0.01 (-0.08%)

SGEN Seattle Genetics
$154.34 /

+2.57 (+1.69%)

SBPH Spring Bank Pharmaceuticals
$1.56 /

-0.085 (-5.17%)

REPL Replimune Group
$18.41 /

-0.14 (-0.75%)

RECN Changed to RGP
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.06 /

-0.11 (-0.29%)

NXTC NextCure
$32.56 /

-0.6 (-1.81%)

MRSN Mersana Therapeutics
$20.50 /

+0.8 (+4.06%)

MRK Merck
$79.24 /

+0.22 (+0.28%)

KURA Kura Oncology
$17.10 /

+0.39 (+2.33%)

KPTI Karyopharm
$18.80 /

+ (+0.00%)

HALO Halozyme
$23.49 /

+0.02 (+0.09%)

EXEL Exelixis
$24.46 /

+0.13 (+0.53%)

DCPH Deciphera
$56.95 /

+0.01 (+0.02%)

CGEN Compugen
$12.92 /

+0.55 (+4.45%)

BPMC Blueprint Medicines
$66.44 /

-0.56 (-0.84%)

BMY Bristol-Myers
$60.18 /

+0.38 (+0.64%)

BLUE Bluebird Bio
$61.30 /

+0.49 (+0.81%)

BCYC Bicycle Therapeutics
$18.28 /

+ (+0.00%)

AZN AstraZeneca
$54.97 /

+1.47 (+2.75%)

AVEO Aveo Pharmaceuticals
$8.01 /

-1.21 (-13.12%)

ATNX Athenex
$11.08 /

-0.04 (-0.36%)

AMGN Amgen
$224.10 /

+0.08 (+0.04%)

ALLO Allogene Therapeutics
$45.80 /

-0.8 (-1.72%)

ABBV AbbVie
$90.97 /

+0.96 (+1.07%)

ABBV AbbVie
$90.97 /

+0.96 (+1.07%)

05/22/20 Piper Sandler
Growth of Biohaven's Nurtec continues to beat AbbVie's Ubrelvy, says Piper
05/21/20 Piper Sandler
Piper Sandler remains Overweight on Synlogic after AbbVie ends collaboration
05/18/20 BofA
AbbVie reinstated with a Neutral at BofA
05/12/20 JPMorgan
AbbVie resumed with an Overweight from Neutral at JPMorgan
ALLO Allogene Therapeutics
$45.80 /

-0.8 (-1.72%)

05/19/20 Roth Capital
Allogene Therapeutics upgraded to Buy with $60 target at Roth Capital
05/19/20 Roth Capital
Allogene Therapeutics upgraded to Buy from Neutral at Roth Capital
05/18/20 H.C. Wainwright
Precision BioSciences could have 'significant upside,' says H.C. Wainwright
05/15/20 Guggenheim
Guggenheim upgrades Allogene to Buy with $50 target after ASCO upside surprise
AMGN Amgen
$224.10 /

+0.08 (+0.04%)

05/28/20 Piper Sandler
Alexion settlement could 'clear the deck' for acquirer, says Piper Sandler
05/28/20 Cowen
Alexion settlement may yield upside surprise, says Cowen
05/28/20 Stifel
Alexion, Amgen appear to have agreed to settlement deal, says Stifel
05/22/20 Piper Sandler
Harpoon Therapeutics initiated with an Overweight at Piper Sandler
ATNX Athenex
$11.08 /

-0.04 (-0.36%)

12/13/19 RBC Capital
Athenex oraxol OS and ORR a 'best case,' buy on weakness, says RBC Capital
12/06/19 SunTrust
Athenex initiated with a Buy at SunTrust
11/19/19 RBC Capital
Athenex gets 'third SABCS win' ahead of meeting, says RBC Capital
08/07/19 RBC Capital
Athenex's Oraxol data 'near best-case,' says RBC Capital
AVEO Aveo Pharmaceuticals
$8.01 /

-1.21 (-13.12%)

05/29/20 Baird
Aveo Pharmaceuticals price target raised to $24 from $15 at Baird
05/01/20 H.C. Wainwright
Aveo Pharmaceuticals price target raised to $10 from $6 at H.C. Wainwright
04/01/20 H.C. Wainwright
Aveo Pharmaceuticals price target raised to $6 from $4 at H.C. Wainwright
03/31/20 Piper Sandler
Aveo Pharmaceuticals price target lowered to $18.50 from $20 at Piper Sandler
AZN AstraZeneca
$54.97 /

+1.47 (+2.75%)

05/29/20 Guggenheim
AstraZeneca price target raised to 10,100 GBp from 9,100 GBp at Guggenheim
05/14/20 Evercore ISI
Evercore ISI says paper 'generally supportive' of AstraZeneca COVID vaccine
05/06/20 Morgan Stanley
AstraZeneca price target raised to 8,630 GBp from 8,600 GBp at Morgan Stanley
05/04/20 Citi
Citi opens 'positive catalyst watch' on AstraZeneca
BCYC Bicycle Therapeutics
$18.28 /

+ (+0.00%)

04/17/20
Fly Intel: Top five analyst initiations
04/17/20 H.C. Wainwright
Bicycle Therapeutics initiated with a Buy at H.C. Wainwright
04/07/20 Piper Sandler
Bicycle Therapeutics' timelines to be impacted by COVID-19, says Piper Sandler
02/25/20 Piper Sandler
Bicycle Therapeutics price target raised to $30 from $20 at Piper Sandler
BLUE Bluebird Bio
$61.30 /

+0.49 (+0.81%)

05/13/20 Stifel
Bluebird's ide-cel remains approvable despite FDA's 'strict stance,' says Stifel
05/13/20 Piper Sandler
Bluebird should be able to easily address RTF issues, says Piper Sandler
05/12/20 RBC Capital
Bluebird Bio initiated with an Outperform at RBC Capital
05/12/20 Oppenheimer
Bluebird Bio price target lowered to $111 from $122 at Oppenheimer
BPMC Blueprint Medicines
$66.44 /

-0.56 (-0.84%)

05/06/20 Nomura Instinet
Deciphera downgraded to Neutral on GIST program risks at Nomura Instinet
05/05/20 Barclays
Blueprint Medicines initiated with an Equal Weight at Barclays
04/29/20 SVB Leerink
Deciphera price target raised to $55 from $50 at SVB Leerink
04/29/20 SVB Leerink
Blueprint Medicines price target lowered to $105 from $125 at SVB Leerink
CGEN Compugen
$12.92 /

+0.55 (+4.45%)

05/26/20 JMP Securities
Compugen resumed with an Outperform at JMP Securities
05/13/20
Fly Intel: Top five analyst initiations
05/13/20 Stifel
Compugen initiated with a Buy at Stifel
05/07/20
Fly Intel: Top five analyst initiations
HALO Halozyme
$23.49 /

+0.02 (+0.09%)

05/26/20 Piper Sandler
Halozyme's Enhanze business nearing accelerated growth, says Piper Sandler
05/12/20 JMP Securities
Halozyme price target raised to $34 from $24 at JMP Securities
05/04/20 Cantor Fitzgerald
Halozyme price target raised to $39 from $35 at Cantor Fitzgerald
03/23/20 Citi
Sarepta, DBV among Citi's SMid Biotech picks amid coronavirus outbreak
EXEL Exelixis
$24.46 /

+0.13 (+0.53%)

05/14/20 SunTrust
Exelixis price target raised to $40 from $35 at SunTrust
05/13/20 Piper Sandler
Exelixis mCRPC data for CABOMETYX may accelerate approval, says Piper Sandler
05/06/20 Piper Sandler
Exelixis price target raised to $30 from $23 at Piper Sandler
04/21/20 Guggenheim
Exelixis price target raised to $32 from $27 at Guggenheim
DCPH Deciphera
$56.95 /

+0.01 (+0.02%)

05/18/20 SunTrust
Deciphera price target raised to $91 from $82 at SunTrust
05/18/20 Barclays
Deciphera price target raised to $85 from $80 at Barclays
05/18/20 Piper Sandler
Piper Sandler a buyer of Deciphera shares on the open
05/15/20 Piper Sandler
Deciphera's Ripretinib approved 3 months ahead of schedule, says Piper Sandler
KURA Kura Oncology
$17.10 /

+0.39 (+2.33%)

05/19/20 Deutsche Bank
Kura Oncology price target lowered to $24 from $28 at Deutsche Bank
05/06/20 Wedbush
Kura prioritizing development of tipifarnib for HRAS-HNSCC, says Wedbush
05/05/20 H.C. Wainwright
Kura Oncology price target lowered to $22 from $29 at H.C. Wainwright
05/05/20 Barclays
Kura Oncology initiated with an Overweight at Barclays
KPTI Karyopharm
$18.80 /

+ (+0.00%)

05/06/20 H.C. Wainwright
Karyopharm price target lowered to $40 from $43 at H.C. Wainwright
04/07/20 Wedbush
Wedbush sees signs of 'potential utility' for Karyopharm's selinexor for COVID
04/07/20 H.C. Wainwright
XPO1 inhibitors have shown promise as COVID-19 treatment, says H.C. Wainwright
03/04/20 Barclays
Karyopharm initiated with an Overweight at Barclays
MRK Merck
$79.24 /

+0.22 (+0.28%)

05/27/20 Alliance Global Partners
PDS Biotechnology initiated with a Buy at Alliance Global Partners
05/20/20 JonesTrading
Merck collaboration positions Surface Oncology well, says JonesTrading
04/27/20 SVB Leerink
Clovis downgraded to Underperform at SVB Leerink as prostate opportunity fades
04/06/20 Raymond James
NGM Biopharmaceuticals initiated with a Strong Buy at Raymond James
BMY Bristol-Myers
$60.18 /

+0.38 (+0.64%)

04/20/20 Piper Sandler
Exelixis combo approval would increase kidney cancer use, says Piper Sandler
MRSN Mersana Therapeutics
$20.50 /

+0.8 (+4.06%)

05/27/20 H.C. Wainwright
Mersana Therapeutics price target raised to $26 from $13 at H.C. Wainwright
04/29/20 BTIG
Mersana Therapeutics initiated with a Buy at BTIG
01/21/20 H.C. Wainwright
Mersana Therapeutics price target raised to $12 from $7 at H.C. Wainwright
08/20/19 H.C. Wainwright
H.C. Wainwright says trial initiation at higher dosing 'bodes well' for Mersana
NXTC NextCure
$32.56 /

-0.6 (-1.81%)

05/26/20 JMP Securities
NextCure initiated with an Outperform at JMP Securities
04/13/20 Piper Sandler
NextCure could report Phase I biomarker data at ASCO, says Piper Sandler
03/24/20 Benchmark
NextCure initiated with a Buy at Benchmark
03/02/20 Roth Capital
NextCure initiated with a Buy at Roth Capital
PFE Pfizer
$38.06 /

-0.11 (-0.29%)

05/21/20 Piper Sandler
Gilead's filgotinib likely being underestimated by Street, says Piper Sandler
05/19/20 H.C. Wainwright
BioNTech upgraded to Buy from Neutral at H.C. Wainwright
05/15/20 Goldman Sachs
After Pfizer data, Goldman says Sarepta remains 'leader' in DMD gene therapy
05/15/20 JPMorgan
JPMorgan still sees Sarepta in pole position in DMD space
RECN Changed to RGP
$0.00 /

+ (+0.00%)

01/03/20 Baird
Resources Connection Q3 guidance 'materially below' expectations, says Baird
10/03/19 JPMorgan
Resources Connection near-term outlook remains challenged, says JPMorgan
REPL Replimune Group
$18.41 /

-0.14 (-0.75%)

05/05/20 Barclays
Replimune Group initiated with an Overweight at Barclays
03/25/20 Wedbush
Replimune Group added to Best Ideas List at Wedbush
11/11/19 Roth Capital
Replimune Group price target raised to $30 from $20 at Roth Capital
09/04/19 Roth Capital
Replimune Group initiated with a Buy at Roth Capital
SBPH Spring Bank Pharmaceuticals
$1.56 /

-0.085 (-5.17%)

04/02/20 Piper Sandler
Piper Sandler keeps Neutral on Spring Bank as study enrollment expected to slow
01/29/20 Jefferies
Spring Bank Pharmaceuticals downgraded to Hold from Buy at Jefferies
01/29/20 Piper Sandler
Piper keeps Neutral rating on Spring Bank after inarigivir discontinued
12/30/19
Fly Intel: Top five analyst actions
SGEN Seattle Genetics
$154.34 /

+2.57 (+1.69%)

05/26/20 Goldman Sachs
Astellas Pharma upgraded to Buy on raised PADCEV estimates at Goldman Sachs
05/26/20 JMP Securities
Seattle Genetics initiated with an Outperform at JMP Securities
05/26/20 Goldman Sachs
Incyte downgraded to Buy from Conviction Buy at Goldman Sachs
05/26/20 Goldman Sachs
Seattle Genetics upgraded to Conviction Buy from Buy at Goldman Sachs
STML Stemline
$11.88 /

-0.01 (-0.08%)

05/05/20 H.C. Wainwright
Stemline downgraded to Neutral from Buy at H.C. Wainwright
05/05/20 Ladenburg
Stemline downgraded to Neutral from Buy at Ladenburg
05/04/20 Alliance Global Partners
Stemline downgraded to Neutral from Buy at Alliance Global Partners
05/04/20 Wedbush
Stemline downgraded to Neutral from Outperform at Wedbush
SYRS Syros Pharmaceuticals
$9.43 /

-0.09 (-0.95%)

04/23/20 JonesTrading
Syros Pharmaceuticals initiated with a Buy at JonesTrading
03/06/20 H.C. Wainwright
Syros Pharmaceuticals price target lowered to $8 from $10 at H.C. Wainwright
01/17/20 Wedbush
Syros Pharmaceuticals risk/reward balanced ahead of data readouts, says Wedbush
01/17/20 Wedbush
Syros Pharmaceuticals downgraded to Neutral from Outperform at Wedbush
TRIL Trillium Therapeutics
$6.20 /

+0.435 (+7.55%)

05/26/20 JMP Securities
Trillium Therapeutics initiated with an Outperform at JMP Securities
08/19/19
Fly Intel: Top five analyst downgrades
08/19/19 H.C. Wainwright
Trillium Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
TROV Changed name to CRDF
$0.00 /

+ (+0.00%)

01/28/20 Noble Capital
Trovagene resumed with an Outperform at Noble Capital
XNCR Xencor
$30.45 /

-0.54 (-1.74%)

05/13/20 Piper Sandler
Xencor's XmAb20717 shows first-ever clinical benefit, says Piper Sandler
03/04/20 Barclays
Barclays starts small, mid cap Biotechnology sector with Positive view
03/04/20 Barclays
Xencor initiated with an Underweight at Barclays
02/25/20 Guggenheim
Xencor upgraded to Buy from Neutral at Guggenheim
XNCR Xencor
$30.45 /

-0.54 (-1.74%)

TRIL Trillium Therapeutics
$6.20 /

+0.435 (+7.55%)

SYRS Syros Pharmaceuticals
$9.43 /

-0.09 (-0.95%)

STML Stemline
$11.88 /

-0.01 (-0.08%)

SGEN Seattle Genetics
$154.34 /

+2.57 (+1.69%)

SBPH Spring Bank Pharmaceuticals
$1.56 /

-0.085 (-5.17%)

REPL Replimune Group
$18.41 /

-0.14 (-0.75%)

RECN Changed to RGP
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.06 /

-0.11 (-0.29%)

NXTC NextCure
$32.56 /

-0.6 (-1.81%)

MRSN Mersana Therapeutics
$20.50 /

+0.8 (+4.06%)

MRK Merck
$79.24 /

+0.22 (+0.28%)

KURA Kura Oncology
$17.10 /

+0.39 (+2.33%)

KPTI Karyopharm
$18.80 /

+ (+0.00%)

HALO Halozyme
$23.49 /

+0.02 (+0.09%)

EXEL Exelixis
$24.46 /

+0.13 (+0.53%)

DCPH Deciphera
$56.95 /

+0.01 (+0.02%)

CGEN Compugen
$12.92 /

+0.55 (+4.45%)

BPMC Blueprint Medicines
$66.44 /

-0.56 (-0.84%)

BMY Bristol-Myers
$60.18 /

+0.38 (+0.64%)

BLUE Bluebird Bio
$61.30 /

+0.49 (+0.81%)

BCYC Bicycle Therapeutics
$18.28 /

+ (+0.00%)

AZN AstraZeneca
$54.97 /

+1.47 (+2.75%)

AVEO Aveo Pharmaceuticals
$8.01 /

-1.21 (-13.12%)

ATNX Athenex
$11.08 /

-0.04 (-0.36%)

AMGN Amgen
$224.10 /

+0.08 (+0.04%)

ALLO Allogene Therapeutics
$45.80 /

-0.8 (-1.72%)

ABBV AbbVie
$90.97 /

+0.96 (+1.07%)

  • 29
    May
TRIL Trillium Therapeutics
$6.20 /

+0.435 (+7.55%)

PFE Pfizer
$38.06 /

-0.11 (-0.29%)

MRK Merck
$79.24 /

+0.22 (+0.28%)

BMY Bristol-Myers
$60.18 /

+0.38 (+0.64%)

AZN AstraZeneca
$54.97 /

+1.47 (+2.75%)

AMGN Amgen
$224.10 /

+0.08 (+0.04%)

ABBV AbbVie
$90.97 /

+0.96 (+1.07%)

XNCR Xencor
$30.45 /

-0.54 (-1.74%)

STML Stemline
$11.88 /

-0.01 (-0.08%)

SGEN Seattle Genetics
$154.34 /

+2.57 (+1.69%)

SBPH Spring Bank Pharmaceuticals
$1.56 /

-0.085 (-5.17%)

PFE Pfizer
$38.06 /

-0.11 (-0.29%)

MRSN Mersana Therapeutics
$20.50 /

+0.8 (+4.06%)

MRK Merck
$79.24 /

+0.22 (+0.28%)

KPTI Karyopharm
$18.80 /

+ (+0.00%)

HALO Halozyme
$23.49 /

+0.02 (+0.09%)

EXEL Exelixis
$24.46 /

+0.13 (+0.53%)

DCPH Deciphera
$56.95 /

+0.01 (+0.02%)

BPMC Blueprint Medicines
$66.44 /

-0.56 (-0.84%)

BMY Bristol-Myers
$60.18 /

+0.38 (+0.64%)

BLUE Bluebird Bio
$61.30 /

+0.49 (+0.81%)

BCYC Bicycle Therapeutics
$18.28 /

+ (+0.00%)

AZN AstraZeneca
$54.97 /

+1.47 (+2.75%)

AVEO Aveo Pharmaceuticals
$8.01 /

-1.21 (-13.12%)

ATNX Athenex
$11.08 /

-0.04 (-0.36%)

AMGN Amgen
$224.10 /

+0.08 (+0.04%)

ALLO Allogene Therapeutics
$45.80 /

-0.8 (-1.72%)

ABBV AbbVie
$90.97 /

+0.96 (+1.07%)

TRIL Trillium Therapeutics
$6.20 /

+0.435 (+7.55%)

RECN Changed to RGP
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.06 /

-0.11 (-0.29%)

MRSN Mersana Therapeutics
$20.50 /

+0.8 (+4.06%)

MRK Merck
$79.24 /

+0.22 (+0.28%)

EXEL Exelixis
$24.46 /

+0.13 (+0.53%)

BMY Bristol-Myers
$60.18 /

+0.38 (+0.64%)

AZN AstraZeneca
$54.97 /

+1.47 (+2.75%)

ABBV AbbVie
$90.97 /

+0.96 (+1.07%)

Conference/Events
Amgen to host conference call » 08:33
05/29/20
05/29
08:33
05/29/20
08:33
AMGN

Amgen

$224.02 /

-0.79 (-0.35%)

Research &…

Research & Development Executive Vice President, along with the Company's clinical investigators, hold a conference call to discuss Amgen's oncology program, including data presented at the ASCO Virtual Scientific Program on May 29 at 4 pm. Webcast Link

ShowHide Related Items >><<
AMGN Amgen
$224.02 /

-0.79 (-0.35%)

AMGN Amgen
$224.02 /

-0.79 (-0.35%)

05/28/20 Piper Sandler
Alexion settlement could 'clear the deck' for acquirer, says Piper Sandler
05/28/20 Cowen
Alexion settlement may yield upside surprise, says Cowen
05/28/20 Stifel
Alexion, Amgen appear to have agreed to settlement deal, says Stifel
05/22/20 Piper Sandler
Harpoon Therapeutics initiated with an Overweight at Piper Sandler
AMGN Amgen
$224.02 /

-0.79 (-0.35%)

AMGN Amgen
$224.02 /

-0.79 (-0.35%)

AMGN Amgen
$224.02 /

-0.79 (-0.35%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.